<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article article-type="research-article" dtd-version="1.2" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">72171</article-id><article-id pub-id-type="doi">10.7554/eLife.72171</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Biochemistry and Chemical Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Short-chain fatty acids activate acetyltransferase p300</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-256078"><name><surname>Thomas</surname><given-names>Sydney P</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8261-1195</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-156011"><name><surname>Denu</surname><given-names>John M</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-9415-0365</contrib-id><email>john.denu@wisc.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Wisconsin Institute for Discovery</institution><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution>Department of Biomolecular Chemistry, University of Wisconsin – Madison</institution><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution>Morgridge Institute for Research</institution><addr-line><named-content content-type="city">Madison</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Cole</surname><given-names>Philip A</given-names></name><role>Senior Editor</role><aff><institution>Harvard Medical School</institution><country>United States</country></aff></contrib></contrib-group><pub-date date-type="publication" publication-format="electronic"><day>22</day><month>10</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e72171</elocation-id><history><date date-type="received" iso-8601-date="2021-07-14"><day>14</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-10-19"><day>19</day><month>10</month><year>2021</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-07-21"><day>21</day><month>07</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.07.21.453192"/></event></pub-history><permissions><copyright-statement>© 2021, Thomas and Denu</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Thomas and Denu</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-72171-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-72171-figures-v2.pdf"/><abstract><p>Short-chain fatty acids (SCFAs) acetate, propionate, and butyrate are produced in large quantities by the gut microbiome and contribute to a wide array of physiological processes. While the underlying mechanisms are largely unknown, many effects of SCFAs have been traced to changes in the cell’s epigenetic state. Here, we systematically investigate how SCFAs alter the epigenome. Using quantitative proteomics of histone modification states, we identified rapid and sustained increases in histone acetylation after the addition of butyrate or propionate, but not acetate. While decades of prior observations would suggest that hyperacetylation induced by SCFAs are due to inhibition of histone deacetylases (HDACs), we found that propionate and butyrate instead activate the acetyltransferase p300. Propionate and butyrate are rapidly converted to the corresponding acyl-CoAs which are then used by p300 to catalyze auto-acylation of the autoinhibitory loop, activating the enzyme for histone/protein acetylation. This data challenges the long-held belief that SCFAs mainly regulate chromatin by inhibiting HDACs, and instead reveals a previously unknown mechanism of HAT activation that can explain how an influx of low levels of SCFAs alters global chromatin states.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>p300/CBP</kwd><kwd>short-chain fatty acids</kwd><kwd>acyl-coenzyme a acyl-coa </kwd><kwd>acyltransferase</kwd><kwd>epigenetics</kwd><kwd>fatty acid metabolism</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mammalian cells</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>GM059785</award-id><principal-award-recipient><name><surname>Denu</surname><given-names>John M</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000001</institution-id><institution>National Science Foundation</institution></institution-wrap></funding-source><award-id>GRFP</award-id><principal-award-recipient><name><surname>Thomas</surname><given-names>Sydney</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>At most physiological concentrations, the short-chain fatty acids propionate and butyrate affect histone acetylation by modifying and activating the acetyltransferase p300/CBP, rather than by inhibiting histone deacetylases.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Short-chain fatty acids (SCFAs) play a crucial role in human health. Although SCFAs include any fatty acid with fewer than six carbons, the first three members of the family—acetate, propionate, and butyrate—are by far the most abundant physiologically (<xref ref-type="bibr" rid="bib34">den Besten et al., 2013</xref>; <xref ref-type="bibr" rid="bib61">Koh et al., 2016</xref>; <xref ref-type="bibr" rid="bib104">Tan et al., 2014</xref>). These three SCFAs are produced in large quantities by bacterial fermentation of nondigestible fiber, and levels can fluctuate based on the amount and type of fiber in the diet (<xref ref-type="bibr" rid="bib9">Bird et al., 2000</xref>; <xref ref-type="bibr" rid="bib34">den Besten et al., 2013</xref>; <xref ref-type="bibr" rid="bib53">Jenkins et al., 1998</xref>; <xref ref-type="bibr" rid="bib68">Levrat et al., 1991</xref>; <xref ref-type="bibr" rid="bib77">Marsono et al., 1993</xref>; <xref ref-type="bibr" rid="bib91">Ríos-Covián et al., 2016</xref>; <xref ref-type="bibr" rid="bib110">Velázquez et al., 2000</xref>). In humans, total SCFA concentrations can reach over 100 mM in the colon, in a ratio of ~60:20:20 acetate:propionate:butyrate (<xref ref-type="bibr" rid="bib30">Cummings et al., 1987</xref>; <xref ref-type="bibr" rid="bib83">Parada Venegas et al., 2019</xref>). SCFAs alone may provide up to 10% of daily caloric requirements in humans (<xref ref-type="bibr" rid="bib6">Bergman, 1990</xref>). Colonocytes are especially prone to metabolize SCFAs, deriving 60–70% of their energy from SCFA oxidation (<xref ref-type="bibr" rid="bib92">Roediger, 1982</xref>). Excess SCFAs are transported to the liver through the portal vein and are eventually released into the peripheral blood, existing at micromolar concentrations (<xref ref-type="bibr" rid="bib10">Bloemen et al., 2009</xref>; <xref ref-type="bibr" rid="bib30">Cummings et al., 1987</xref>).</p><p>Butyrate and acetate are the most-studied members of the group. Acetate plays vital roles in cellular metabolism, especially as a building block for the central metabolite acetyl-CoA (<xref ref-type="bibr" rid="bib13">Bose et al., 2019</xref>; <xref ref-type="bibr" rid="bib73">Liu et al., 2018</xref>; <xref ref-type="bibr" rid="bib120">Zhao et al., 2016</xref>). The physiological effects of butyrate are abundant: butyrate has been reported among other things to improve intestinal barrier function (<xref ref-type="bibr" rid="bib20">Chang et al., 2014</xref>; <xref ref-type="bibr" rid="bib46">Hamer et al., 2007</xref>; <xref ref-type="bibr" rid="bib84">Peng et al., 2009</xref>), reduce inflammation (<xref ref-type="bibr" rid="bib24">Chriett et al., 2019</xref>; <xref ref-type="bibr" rid="bib109">Usami et al., 2008</xref>; <xref ref-type="bibr" rid="bib111">Vinolo et al., 2011</xref>), improve metabolic health (<xref ref-type="bibr" rid="bib39">Gao et al., 2009</xref>; <xref ref-type="bibr" rid="bib70">Lin et al., 2012</xref>; <xref ref-type="bibr" rid="bib80">Müller et al., 2019</xref>), and prevent cancer (<xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>; <xref ref-type="bibr" rid="bib45">Hague et al., 1993</xref>). The role of propionate is less clear—while it shows the same beneficial effects as butyrate in many studies, extremely high levels of propionate are associated with negative health outcomes such as propionic acidemia and autism spectrum disorders (<xref ref-type="bibr" rid="bib1">Abdelli et al., 2019</xref>; <xref ref-type="bibr" rid="bib2">Al-Lahham et al., 2010</xref>; <xref ref-type="bibr" rid="bib69">Li et al., 2017</xref>).</p><p>It is generally believed that SCFAs induce physiological effects by changing the cell’s epigenetic state (<xref ref-type="bibr" rid="bib46">Hamer et al., 2007</xref>; <xref ref-type="bibr" rid="bib48">Hinnebusch et al., 2002</xref>; <xref ref-type="bibr" rid="bib64">Krautkramer et al., 2016</xref>; <xref ref-type="bibr" rid="bib104">Tan et al., 2014</xref>). Epigenetics describes the regulation that takes place in eukaryotic chromatin. Much of this regulation centers around histone proteins, which are heavily decorated with post-translational modifications (PTMs). Histone PTMs affect a wide array of processes, from DNA accessibility to transcription factor binding (<xref ref-type="bibr" rid="bib4">Bannister and Kouzarides, 2011</xref>; <xref ref-type="bibr" rid="bib56">Karch et al., 2013</xref>; <xref ref-type="bibr" rid="bib62">Kouzarides, 2007</xref>). Histone PTMs include lysine acetylation, which opens chromatin and makes it more accessible to transcription, and lysine methylation, which performs various functions. Recently, a host of other histone PTMs have also been identified, including lysine propionylation and butyrylation (<xref ref-type="bibr" rid="bib21">Chen et al., 2007</xref>; <xref ref-type="bibr" rid="bib31">Dai et al., 2014</xref>; <xref ref-type="bibr" rid="bib43">Goudarzi et al., 2016</xref>; <xref ref-type="bibr" rid="bib57">Kebede et al., 2017</xref>).</p><p>Histone PTMs, as well as the enzymes which add or remove them, are exquisitely sensitive to changes in cellular metabolism (<xref ref-type="bibr" rid="bib3">Albaugh et al., 2011</xref>; <xref ref-type="bibr" rid="bib37">Fan et al., 2015</xref>; <xref ref-type="bibr" rid="bib95">Sassone-Corsi, 2013</xref>). Several central metabolites are also substrates for histone modifications: such as acetyl-CoA, which is used to acetylate histones. Histone acetylation is regulated on two fronts—first by histone acetyltransferases (HATs), which transfer acetyl groups to chromatin, and then by histone deacetylases (HDACs), which remove them (<xref ref-type="bibr" rid="bib3">Albaugh et al., 2011</xref>). Acetate, propionate, and butyrate have all been reported to inhibit HDACs to varying extents, with butyrate being the most potent inhibitor (<xref ref-type="bibr" rid="bib12">Bolduc et al., 2017</xref>; <xref ref-type="bibr" rid="bib16">Candido et al., 1978</xref>; <xref ref-type="bibr" rid="bib33">Davie, 2003</xref>; <xref ref-type="bibr" rid="bib49">Hsu et al., 2016</xref>; <xref ref-type="bibr" rid="bib100">Silva et al., 2018</xref>; <xref ref-type="bibr" rid="bib113">Waldecker et al., 2008</xref>). HDAC inhibition has been proposed as a mechanism for SCFA’s anti-cancer effects (<xref ref-type="bibr" rid="bib36">Donohoe et al., 2014</xref>; <xref ref-type="bibr" rid="bib48">Hinnebusch et al., 2002</xref>), insulin regulation (<xref ref-type="bibr" rid="bib24">Chriett et al., 2019</xref>; <xref ref-type="bibr" rid="bib39">Gao et al., 2009</xref>), and immunomodulation (<xref ref-type="bibr" rid="bib12">Bolduc et al., 2017</xref>; <xref ref-type="bibr" rid="bib20">Chang et al., 2014</xref>; <xref ref-type="bibr" rid="bib109">Usami et al., 2008</xref>; <xref ref-type="bibr" rid="bib111">Vinolo et al., 2011</xref>). However, there are still questions as to whether SCFAs regulate the epigenome by HDAC inhibition alone (<xref ref-type="bibr" rid="bib27">Corfe, 2012</xref>; <xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>; <xref ref-type="bibr" rid="bib41">Gibson, 2000</xref>).</p><p>It has been recently reported that the gut microbiome can affect histone modifications systemically (<xref ref-type="bibr" rid="bib64">Krautkramer et al., 2016</xref>; <xref ref-type="bibr" rid="bib65">Kumar et al., 2014</xref>; <xref ref-type="bibr" rid="bib93">Romano et al., 2017</xref>; <xref ref-type="bibr" rid="bib103">Takahashi et al., 2006</xref>; <xref ref-type="bibr" rid="bib115">Wellen et al., 2009</xref>; <xref ref-type="bibr" rid="bib121">Zhao et al., 2020a</xref>). Our lab has demonstrated that germ-free mice display distinct patterns of histone PTMs in multiple tissues (<xref ref-type="bibr" rid="bib64">Krautkramer et al., 2016</xref>). This phenotype was complex, but could be generally characterized by decreased histone acetylation on multiple sites. However, acetylation levels did not depend solely on bacteria—colonized mice fed diets that produced low levels of SCFAs showed similar PTMs to germ-free mice. Finally, simply supplementing germ-free mice with SCFAs in drinking water led to changes in gene expression and histone PTMs that mimicked bacterial colonization. This data strongly suggests that SCFAs are a critical link between the microbiome and epigenetic state. Our understanding of this cross-talk is still in its infancy; thus, discovering how SCFAs interact with host cells on a mechanistic level is crucial to understanding how these systems interact as a whole. Here, we integrate proteomics and metabolomics with biochemical assays to investigate how each SCFA affects epigenetics and cell metabolism. Our results suggest that at physiologic levels, SCFAs induce histone acetylation by activating HATs instead of inhibiting HDACs.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>Propionate and butyrate induce hyperacetylation in cell culture</title><p>To determine the broad effects of extracellular SCFAs on histone PTMs, we treated HCT116 cells with acetate, propionate, and butyrate individually and then performed histone proteomics (<xref ref-type="bibr" rid="bib56">Karch et al., 2013</xref>; <xref ref-type="bibr" rid="bib63">Krautkramer et al., 2015</xref>). This mass spectrometry-based method allows for simultaneous analysis of &gt;70 histone PTMs, which significantly improves on traditional Western blotting (<xref ref-type="bibr" rid="bib106">Thomas et al., 2020</xref>). While the impact of SCFAs on a few of these PTMs has been studied previously, to our knowledge this is the first study to show how SCFAs regulate a range of both canonical and non-canonical PTMs (<xref ref-type="bibr" rid="bib48">Hinnebusch et al., 2002</xref>; <xref ref-type="bibr" rid="bib60">Kiefer et al., 2006</xref>; <xref ref-type="bibr" rid="bib100">Silva et al., 2018</xref>; <xref ref-type="bibr" rid="bib114">Wang et al., 2018</xref>). HCT116 cells were initially chosen because they are derived from colon, and colon cells are in most frequent contact with bacterially produced SCFAs.</p><p>Propionate and butyrate induced rapid and dose-dependent increases in histone acetylation but did not affect histone methylation (<xref ref-type="fig" rid="fig1">Figure 1A</xref>). In contrast, acetate had no significant effect on histone PTMs at any dose or time point tested. These results are consistent with previous reports (<xref ref-type="bibr" rid="bib48">Hinnebusch et al., 2002</xref>; <xref ref-type="bibr" rid="bib60">Kiefer et al., 2006</xref>; <xref ref-type="bibr" rid="bib100">Silva et al., 2018</xref>). The hyperacetylation phenotype with propionate and butyrate was rapid and stable, persisting for at least 24 hr (<xref ref-type="fig" rid="fig1">Figure 1B</xref>). We also detected changes in both histone propionylation and butyrylation on multiple sites, including significant increases in K18/K23 propionylation after both propionate and butyrate treatment. In general, changes in histone propionylation and butyrylation were less consistent across experiments compared to the robust changes in histone acetylation, likely due in part to the technical challenges of measuring low-abundance propionylation/butyrylation. Based on these experiments, we chose a standard treatment of 1 mM SCFA for 1 hr, which we used for further experiments unless otherwise indicated. This dose did not affect media pH, media glucose, or cell viability for at least 24 hr (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>). The 1 mM dose is within the physiological concentrations in the colon (which range from 0.5 to 15 mM), but is higher than reported concentrations in other parts of the body (which range from 0 to 150 µM) (<xref ref-type="bibr" rid="bib30">Cummings et al., 1987</xref>; <xref ref-type="bibr" rid="bib83">Parada Venegas et al., 2019</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Extracellular propionate and butyrate induce histone hyperacetylation.</title><p>(<bold>A</bold>) Histone proteomics of HCT116 cells treated with 1 mM acetate, propionate, or butyrate for 1 hr. (<bold>B</bold>) Histone acylation over a time course of 1 mM acetate, propionate, or butyrate treatment. (<bold>C</bold>) SCFA treatment (1 mM, 1 hr). of HEK293, MCF7, and HepG2 cell lines. All values are log<sub>2</sub>(fold change) over untreated, time-matched controls. *=p≤0.05, **=p≤0.01, ***=p≤0.001. n=3 per condition.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Physiological effects of SCFA treatment.</title><p>(<bold>A</bold>) Histone proteomics of HCT116 cells treated with 0.01, 0.1, or 1 mM acetate, propionate, or butyrate for 1 hr. Values are log<sub>2</sub>(fold change) over untreated control. *=p≤0.05, **=p≤0.01, ***=p≤0.001. (<bold>B</bold>) Media pH of HCT116 cells over 24 SCFA treatment. (<bold>C</bold>) Media glucose concentration over 24 hr SCFA treatment. (<bold>D</bold>) Cytotoxicity curves for acetate, propionate, and butyrate after 24 hr treatment. (<bold>E</bold>) Values used for HDAC inhibition calculations in <xref ref-type="table" rid="table1">Table 1</xref>. All experiments were repeated at least two times with an n=3 per condition, representative data is shown. Raw values for B-E can be found in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. HDAC, histone deacetylase; SCFA, short-chain fatty acid.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig1-figsupp1-v2.tif"/></fig></fig-group><p>To determine whether this effect was unique to HCT116 cells, we also treated three other cell lines derived from diverse human tissues. HEK293, HepG2, and MCF7 cells showed remarkably similar hyperacetylation phenotypes after propionate and butyrate treatment (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). Thus, the ability of propionate and butyrate to increase histone acetylation, but not methylation, can be generalized to multiple cell types.</p></sec><sec id="s2-2"><title>Propionate and butyrate are rapidly metabolized into acyl-CoAs</title><p>This experiment raised several intriguing questions. First, what differentiates propionate and butyrate from acetate? It is general knowledge that butyrate can act as an HDAC inhibitor, slowing the removal of acetate from chromatin (<xref ref-type="bibr" rid="bib33">Davie, 2003</xref>). This could explain the difference between acetate and butyrate, but it does not necessarily explain the difference between acetate and propionate. To test whether propionate could act as an HDAC inhibitor in HCT116 cells, we performed HDAC assays on nuclear extract and determined the apparent IC<sub>50</sub> values for these SCFAs and their corresponding acyl-CoA forms. <xref ref-type="table" rid="table1">Table 1</xref> lists the IC<sub>50</sub> values of HDAC inhibition for propionate, butyrate, and corresponding acyl-CoAs. These IC<sub>50</sub> values are on the low end of previously published values, which range from 50 to 300 µM in nuclear extract and 1–10 mM in whole cells (<xref ref-type="bibr" rid="bib50">Huber et al., 2011</xref>; <xref ref-type="bibr" rid="bib100">Silva et al., 2018</xref>; <xref ref-type="bibr" rid="bib111">Vinolo et al., 2011</xref>; <xref ref-type="bibr" rid="bib113">Waldecker et al., 2008</xref>). While SCFA concentrations in media were theoretically higher than our determined IC<sub>50</sub> values (<xref ref-type="fig" rid="fig2">Figure 2C</xref>), it has been previously reported that intracellular concentrations of SCFAs are much lower than extracellular concentrations, which could have bearing on this mechanism (<xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Metabolism of extracellular short-chain fatty acids (SCFAs).</title><p>(<bold>A</bold>) Overall scheme of SCFA metabolism. (<bold>B</bold>) Proportion of <sup>13</sup>C on histones after 4 hr treatment with labeled SCFAs. (<bold>C</bold>) Concentration of SCFAs in media (µM) and in cells (femtomole/cell) over a 24 hr time course. (<bold>D, E</bold>) <sup>13</sup>C labeling of TCA cycle metabolites (<bold>D</bold>) and acyl-carnitines (<bold>E</bold>) over a 24-hr time course. Values are average and standard deviation of normalized signal intensity of ≥3 biological replicates.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig2-v2.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Further SCFA metabolism.</title><p>(<bold>A</bold>) Total carnitine and CoA levels in SCFA-treated cells over 24 hr time course. (<bold>B</bold>) Acyl-carnitine labeling in HCT116, HEK293, HepG2, and MCF7 cells after 1 hr treatment with 1 mM SCFA. Values are normalized signal intensity. (<bold>C</bold>) SCFA concentrations in media incubated in dishes with or without cells over a 24-hr time course. (<bold>D</bold>) Acetyl-CoA, propionyl-CoA, and butyryl-CoA labeling in HCT116 cells treated with 1 mM SCFA over a 24-hr time course. All values are average and standard deviation of ≥3 biological replicates. SCFA, short-chain fatty acid.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig2-figsupp1-v2.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>Metabolism of SCFAs to acetyl-CoA is not necessary to induce hyperacetylation.</title><p>(<bold>A</bold>) Propionate and butyrate increase acetylation in HCT116 cells treated with non-targeting (NT) siRNA and 1 mM SCFA. (<bold>B</bold>) ACLY, ACSS2, and PCC siRNAs compared to NT siRNA + same SCFA treatment. (<bold>C</bold>) Knockdown efficiency of ACLY and ACSS2 siRNAs in cells treated with SCFAs. Full blots can be found in <xref ref-type="supplementary-material" rid="sdata2">Source data 2</xref>. (<bold>D</bold>) Methylmalonyl-CoA production in primary lymphoblasts from patients with propionic acidemia (KO 1/2) and family-matched controls (WT 1/2). Propionic acidemia is a rare genetic disease caused by mutations in PCC. Methylmalonyl-CoA is the product of PCC and was measured via HPLC. (<bold>E</bold>) Propionate and butyrate induce hyperacetylation in primary lymphoblasts from KO1/2 and WT1/2 cells. (<bold>F</bold>) Knockout of PCC does not affect histone hyperacetylation. Values are compared to WT cells + same SCFA treatment. For all samples, *=p≤0.05, **=p≤0.01, ***=p≤0.001. n=3 per condition. SCFA, short-chain fatty acid.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig2-figsupp2-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>IC<sub>50</sub> of HDAC inhibition for SCFAs and acyl-CoAs.</title><p>IC<sub>50</sub> values of HDAC inhibition for propionate, butyrate, propionyl-CoA, and butyryl-CoA. Values are calculated from dose curves using n=2 technical replicates, raw data can be found in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Molecule</th><th align="left" valign="bottom">IC<sub>50</sub></th></tr></thead><tbody><tr><td align="left" valign="bottom">Propionate</td><td align="char" char="." valign="bottom">223 ± 64 µM</td></tr><tr><td align="left" valign="bottom">Butyrate</td><td align="char" char="." valign="bottom">52 ± 11 µM</td></tr><tr><td align="left" valign="bottom">Propionyl-CoA</td><td align="char" char="." valign="bottom">18 ± 7 mM</td></tr><tr><td align="left" valign="bottom">Butyryl-CoA</td><td align="left" valign="bottom">1.13 ± 0.01 mM</td></tr></tbody></table></table-wrap><p>To determine intracellular SCFA concentrations before and after the extracellular addition of SCFAs, we treated cells with fully labeled <sup>13</sup>C-acetate, propionate, or butyrate and ran targeted LC-MS/MS metabolomics to track SCFAs through cellular metabolism (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). After treatments, SCFA concentrations in media declined from 1 mM to 0.5 mM over 24 hr. SCFA levels measured in cellular extractions were similar among the three SCFAs (max ~3-fold difference), with all showing a decline by 24 hr (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). From levels determined in the cellular extractions, we estimated intracellular concentrations of ~40 µM for butyrate and ~100 µM for propionate and acetate, which are consistent with previous reports (<xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>). In additional control experiments, SCFA concentrations in media without cells incubated at 37°C declined at almost an identical rate as that observed in media incubated with cells, suggesting that the bulk of the decrease in media SCFA concentration was due to volatility and not to cellular consumption (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). The calculated values suggest that free SCFAs are rapidly metabolized instead of building up in cells (<xref ref-type="bibr" rid="bib11">Boets et al., 2017</xref>; <xref ref-type="bibr" rid="bib25">Clausen and Mortensen, 1994</xref>; <xref ref-type="bibr" rid="bib26">Clausen and Mortensen, 1995</xref>). With this in mind, we searched for labeled carbons in downstream TCA cycle metabolites. However, we found no significant labeling of TCA cycle metabolites after propionate and butyrate treatment (<xref ref-type="fig" rid="fig2">Figure 2D</xref>). Instead, labeled carbons built up as acyl-carnitine species, appearing in as little as 10 min and remaining stable for 24 hrs (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). Intriguingly, this buildup did not occur in acetate-treated cells. The same trend occurred in acyl-CoA levels, although these species degrade rapidly during sample processing and are thus difficult to detect by mass spectrometry (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Accumulation of acyl-CoAs after SCFA treatment has been previously reported (<xref ref-type="bibr" rid="bib5">Basu et al., 2011</xref>). In that study, increases in acyl-CoA lead to a decrease of free coenzyme A. Under our conditions, however, free carnitine and free CoA levels did not significantly change (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). To confirm that these metabolic changes were consistent across cell lines, we also performed targeted LC-MS/MS metabolomics in HEK293, HepG2, and MCF7 cells. All cell lines showed the same upregulation of acyl-carnitines after butyrate and propionate treatment (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1</xref>). Ultimately, these data suggest that histone hyperacetylation may not be due to the presence of intracellular propionate or butyrate, as the intracellular levels of these metabolites are low, but to the presence of propionyl- or butyryl-CoA. Since propionyl- and butyryl-CoA do not inhibit HDAC at physiological concentrations, this raises the possibility that the histone hyperacetylation phenotype may not be due to HDAC inhibition, but to a different mechanism (<xref ref-type="table" rid="table1">Table 1</xref>; <xref ref-type="bibr" rid="bib112">Vogelauer et al., 2012</xref>).</p><p>The intracellular levels of SCFAs do not support robust HDAC inhibition at micromolar treatment concentrations. However, we and others have measured histone hyperacetylation in response to treatment concentrations as low as 10 µM (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib8">Biermann et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>; <xref ref-type="bibr" rid="bib59">Kespohl et al., 2017</xref>). At these concentrations, HDACs would be inhibited &lt;1%. Alternatively, it has been proposed that hyperacetylation under SCFA treatment is due to a direct mechanism, in which acetyl-CoA generated by SCFAs is added directly onto histones (<xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>). To test whether this occurred in our system, we performed histone proteomics after a 4-hr treatment with <sup>13</sup>C-labeled SCFAs. This treatment only resulted in 1–5% <sup>13</sup>C-labeling on histones, which cannot account for the two- or threefold increases in histone acetylation seen after SCFA treatment (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). This indicates that the majority of new acetyl groups (~90–95%) were not generated from labeled SCFAs. To confirm that SCFAs do not need to be metabolized into acetyl-CoA to induce hyperacetylation, we knocked down several enzymes involved in acetyl-CoA generation from SCFAs (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). siRNA knockdown or genetic knockout of ACLY (an enzyme involved in transport of acetyl-CoA out of the mitochondria), ACSS2 (the cytoplasmic acetyl-CoA ligase), and PCC (an enzyme in the pathway that metabolizes propionyl-CoA to succinyl-CoA) had no significant effect on propionate or butyrate-induced histone acetylation (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). This data indicates that acyl-CoAs are not metabolized to acetyl-CoA in sufficient quantities to explain the induced hyperacetylation, indicating a different mechanism is at play.</p></sec><sec id="s2-3"><title>Propionyl- and butyryl-CoA activate histone acetylation</title><p>Next, we tested whether the rapidly formed propionyl- and butyryl-CoA from propionate and butyrate treatment could directly activate HATs (<xref ref-type="table" rid="table1">Table 1</xref>). HAT assays demonstrated that propionyl- and butyryl-CoA induced dose-dependent increases in the HAT activity of nuclear extract (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). Free propionate and butyrate had no effect. However, since this assay simply measures the release of CoA, the apparent increase in HAT activity could have resulted from increased propionyl- or butyryl-transfer reactions. In addition, these results do not indicate which HAT enzymes may be activated.</p><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Acyl-CoAs activate p300.</title><p>(<bold>A</bold>) HAT activity of nuclear extract treated with a dose curve of SCFAs and acyl-CoAs. (<bold>B</bold>) Rate of p300 auto-acylation with acetyl-CoA, propionyl-CoA, and butyryl-CoA. Values are average and standard deviation, n=4 per condition. (<bold>C</bold>) Rate of histone acetylation by acetylated, propionylated, or butyrylated p300 using radioactive acetyl-CoA. Values are average and standard deviation, n=3 per condition. Replicate results from this assay performed with different enzyme preparations on different days are shown in <xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>. Quantification for all replicates including Western blots and radioactive assays available in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>. HAT, histone acetyltransferase; SCFA, short-chain fatty acid.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Recombinant p300 is actively auto-acylated.</title><p>(<bold>A</bold>) Acylation of active or denatured p300. (<bold>B</bold>) SIRT2 treatment removes endogenous acetylation on recombinant p300 without inhibiting auto-acetylation after add-back of acetyl-CoA. (<bold>C</bold>) Rate of histone acetylation after incubation with untreated, acetylated, propionylated, or butyrylated p300 using Westerns blots and H3/H4 dimers. (<bold>D</bold>) Graphical representation of histone blots. All gels are representative of at least three independent experiments performed on separate days. (<bold>E</bold>) Radioactivity assays showing the rate of acetylation by acetylated, propionylated, or butyrylated p300. Each replicate was performed with a different acylated enzyme preparation on a different day. Values and image quantification for all replicates available in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>, full blots can be found in <xref ref-type="supplementary-material" rid="sdata2">Source data 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig3-figsupp1-v2.tif"/></fig></fig-group><p>HATs can be categorized into three main families—GNAT, MYST, and p300/CBP (<xref ref-type="bibr" rid="bib3">Albaugh et al., 2011</xref>; <xref ref-type="bibr" rid="bib7">Berndsen and Denu, 2008</xref>; <xref ref-type="bibr" rid="bib37">Fan et al., 2015</xref>). Most HATs prefer specific histone lysines and catalyze acetyl-transfer to a handful of histone substrates (<xref ref-type="bibr" rid="bib94">Roth et al., 2001</xref>). However, p300/CBP acetylates a large number of lysine sites in vitro, and is known to target several of our measured hyperacetylation sites in vivo (<xref ref-type="bibr" rid="bib47">Henry et al., 2013</xref>). p300/CBP are two closely related transcriptional co-activators—large proteins consisting of several domains and even more binding partners and acetylation targets (<xref ref-type="bibr" rid="bib19">Chan and La Thangue, 2001</xref>; <xref ref-type="bibr" rid="bib32">Dancy and Cole, 2015</xref>; <xref ref-type="bibr" rid="bib42">Goodman and Smolik, 2000</xref>). Both proteins encode an autoinhibitory loop (AIL, also called the autoregulatory or activation loop), which must be auto-acetylated to stimulate HAT activity (<xref ref-type="bibr" rid="bib55">Karanam et al., 2006</xref>; <xref ref-type="bibr" rid="bib107">Thompson et al., 2004</xref>). Large-scale mass-spectrometry surveys have identified sites of propionylation and butyrylation on p300, including on several AIL lysines; however, how these modifications are added and whether they have a functional consequence on p300 activity are not known (<xref ref-type="bibr" rid="bib21">Chen et al., 2007</xref>; <xref ref-type="bibr" rid="bib22">Cheng et al., 2009</xref>; <xref ref-type="bibr" rid="bib54">Kaczmarska et al., 2017</xref>). First, we determined whether unmodified p300 can catalyze auto-acylation using propionyl- or butyryl-CoA. Indeed, we found that recombinant p300 performed auto-acylation with propionyl- or butyryl-CoA at rates indistinguishable from auto-acetylation with acetyl-CoA (<xref ref-type="fig" rid="fig3">Figure 3B</xref>). Auto-acylation was catalytic, as heat-denatured p300 did not show increases in acylation under the same conditions (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1A</xref>). Proteomics analysis confirmed the location of propionylation and butyrylation on several AIL lysine sites under these conditions (<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Sites of p300 acylation.</title><p>Sites of lysine acetylation, propionylation, and butyrylation on recombinant p300 treated with acyl-CoAs. AIL: autoinhibitory loop, A: acetylation, P: propionylation, B: butyrylation.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Lysine site(AIL lysines in bold).</th><th align="left" valign="bottom">Acetylation</th><th align="left" valign="bottom">Propionylation</th><th align="left" valign="bottom">Butyrylation</th></tr></thead><tbody><tr><td align="left" valign="bottom">K1542</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">P</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">K1546</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">P</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">K1549</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">P</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">K1550</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">K1551</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">P</td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">K1554</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">P</td><td align="left" valign="bottom">B</td></tr><tr><td align="left" valign="bottom">K1555</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">P</td><td align="left" valign="bottom">B</td></tr><tr><td align="left" valign="bottom"><bold>K1558</bold></td><td align="left" valign="bottom"><bold>A</bold></td><td align="left" valign="bottom"><bold>P</bold></td><td align="left" valign="bottom"><bold>B</bold></td></tr><tr><td align="left" valign="bottom"><bold>K1560</bold></td><td align="left" valign="bottom"><bold>A</bold></td><td align="left" valign="bottom"><bold>P</bold></td><td align="left" valign="bottom"><bold>B</bold></td></tr><tr><td align="left" valign="bottom"><bold>K1568</bold></td><td align="left" valign="bottom"><bold>A</bold></td><td align="left" valign="bottom"><bold>P</bold></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"><bold>K1569</bold></td><td align="left" valign="bottom"><bold>A</bold></td><td align="left" valign="bottom"><bold>P</bold></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"><bold>K1570</bold></td><td align="left" valign="bottom"><bold>A</bold></td><td align="left" valign="bottom"><bold>P</bold></td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"><bold>K1583</bold></td><td align="left" valign="bottom"><bold>A</bold></td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom"><bold>K1590</bold></td><td align="left" valign="bottom"><bold>A</bold></td><td align="left" valign="bottom"> </td><td align="left" valign="bottom"> </td></tr><tr><td align="left" valign="bottom">K1637</td><td align="left" valign="bottom">A</td><td align="left" valign="bottom">P</td><td align="left" valign="bottom"> </td></tr></tbody></table></table-wrap><p>Next, we investigated if auto-acylation activates p300 toward histone acetylation. To do so, we compared pre-acylated and unmodified forms of recombinant p300 in radioactive HAT assays to measure acetylation rates on a K18/K23-containing peptide substrate. All forms of acylated p300 (acetylated, propionylated, and butyrylated) were significantly more active than an unmodified control (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In addition, there were no significant differences in the activity of auto-acetylated, propionylated, or butyrylated p300, which all showed ~500% increase in their initial rates compared to unmodified p300. We confirmed these results by performing Western blot HAT activity assays with full-length histone H3/H4 dimers/tetramers, which are a more physiological substrate than a single peptide (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1C-D</xref>). Again, these data showed an increase in activity for all three forms of acylated p300. In all, these data demonstrate that p300 catalyzes auto-butyrylation and propionylation on AIL sites, and that auto-acylation activates the enzyme in a similar manner to auto-acetylation.</p><p>To investigate whether this previously unappreciated mechanism functions in vivo, we used pharmacological inhibitors of each potential pathway. To minimize any potential effects from HDAC inhibition in these experiments, we used treatment concentrations from 100 to 250 µM, which should lead to no more than 5–15% HDAC inhibition (<xref ref-type="table" rid="table1">Table 1</xref>). First, we treated cells with a potent inhibitor of p300, A485. A485 inhibits both histone acetylation and auto-acetylation of p300, and thus should inhibit histone hyperacetylation due to p300 activation (<xref ref-type="bibr" rid="bib66">Lasko et al., 2017</xref>). Indeed, A485 treatment reversed SCFA-induced hyperacetylation on p300 targets H3K27 and H3K18 (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). A485 treatment did not just reverse SCFA-induced hyperacetylation on histone substrates of p300, but also on the non-histone p300 substrate p53 (K382). Second, we treated cells with the potent HDAC inhibitor, SAHA. Both SAHA and butyrate are thought to be competitive inhibitors of HDACs, although the IC<sub>50</sub> of SAHA is significantly lower (~10 nm) (<xref ref-type="bibr" rid="bib76">Marks and Breslow, 2007</xref>; <xref ref-type="bibr" rid="bib96">Sekhavat et al., 2007</xref>). Treatment with 10 µM of this potent pan-HDAC inhibitor should effectively saturate HDAC inhibition, at least of class I and II HDACs, which are known to target these sites (<xref ref-type="bibr" rid="bib18">Caslini et al., 2019</xref>; <xref ref-type="bibr" rid="bib58">Kelly et al., 2018</xref>; <xref ref-type="bibr" rid="bib88">Rajan et al., 2018</xref>). Thus, if propionate and butyrate act solely as HDAC inhibitors, they should not induce further hyperacetylation under these conditions. However, 100 µM treatment of propionate or butyrate with SAHA still led to significant increases in p53K382 acetylation over a SAHA control (<xref ref-type="fig" rid="fig4">Figure 4A</xref>, <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Collectively, these results suggest that propionate and butyrate induce histone hyperacetylation by an alternative mechanism to HDAC inhibition, likely through the auto-activation of p300 by rapidly formed acyl-CoAs.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>p300 inhibition, but not HDAC inhibition, reverses SCFA-induced hyperacetylation.</title><p>(<bold>A</bold>) Acetylation of H3K27ac, H3K18ac, and p53K382ac after treatment with A485, SAHA, and 100–250 µM of propionate/butyrate for 24 hr. Values are normalized to total H3 or total p53 before calculating fold changes to the appropriate untreated control. (<bold>B</bold>) Acetylation of H3K27ac and H3K18ac in cells transfected with sham, WT p300, or ΔGlu p300 plasmids. Values are fold change over untreated cells with the same transfection. (<bold>C</bold>) Activity of immunoprecipitated p300 after treatment with 500 µM of propionate or butyrate. Activity is measured with a radioactive assay and normalized to concentration of immunoprecipitated p300 in each sample. *=p≤0.05, **=p≤0.01, ***=p≤0.001. n≥3 per condition. HDAC, histone deacetylase; SCFA, short-chain fatty acid.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig4-v2.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Representative Western blots corresponding to <xref ref-type="fig" rid="fig4">Figure 4</xref>.</title><p>(<bold>A</bold>) Acetylation of H3K27ac, H3K18ac, and p53K382ac after treatment with A485, SAHA, and 100–250 µM of propionate/butyrate for 24 hr. (<bold>B</bold>) Expression of HA-tagged plasmids and p300 levels in cells transfected with sham, WT p300, or ΔGlu p300. (<bold>C</bold>) Levels of H3K27ac, H3K18ac, and H3 in sham, WT p300, or ΔGlu p300-transfected cells. (<bold>D</bold>) Levels of p300, butyrylation, and propionylation in p300 immunoprecipitated from HCT116 cells treated with 500 µM propionate or butyrate for 1 hr. All experiments were performed at least two separate times with n=3 biological replicates. Values and image quantification for all replicates available in <xref ref-type="supplementary-material" rid="sdata1">Source data 1</xref>, full blots can be found in <xref ref-type="supplementary-material" rid="sdata2">Source data 2</xref>.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-72171-fig4-figsupp1-v2.tif"/></fig></fig-group><p>To corroborate this novel mechanism of SCFA action on chromatin, we transfected HCT116 cells with two full-length p300 constructs: either wild-type (WT) p300 or an AIL mutant in which 11 of the 17 AIL lysines were mutated to a glutamate (ΔGlu) (<xref ref-type="bibr" rid="bib82">Ortega et al., 2018</xref>). The ΔGlu mutation changes the charge on AIL sites, which in turn blocks auto-acylation of the AIL and prevents p300 activation. As expected, 500 µM propionate treatment induced significant increases in histone acetylation after sham and WT transfections (<xref ref-type="fig" rid="fig4">Figure 4B</xref><bold>,</bold> <xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B-C</xref>). However, cells transfected with the ΔGlu mutant showed significantly smaller increases in acetylation, approximately half of that seen in WT-transfected cells. In addition, we suspect that even the small increases in acetylation in the ΔGlu condition were due to residual amounts of endogenous p300 in transfected cells, or possibly acylation of residual lysine sites on the AIL. Nevertheless, these data strongly suggest that the AIL lysines of p300 are necessary to induce the full extent of histone hyperacetylation after propionate treatment.</p><p>Finally, we performed immunoprecipitation of full-length endogenous p300 from HCT116 cells treated with 500 µM propionate or butyrate. p300 immunoprecipitated from propionate and butyrate-treated cells showed small but significant increases in activity in a radioactive HAT assay (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). Corresponding western blots also identified increased propionylation and butyrylation of p300 under these conditions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1D</xref>). In all, our results demonstrate that p300 activation, rather than HDAC inhibition, plays a critical role for propionate and butyrate-induced chromatin hyperacetylation at low concentrations.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>For decades, butyrate and propionate’s ability to alter chromatin have been attributed to HDAC inhibition (<xref ref-type="bibr" rid="bib16">Candido et al., 1978</xref>). However, the IC<sub>50</sub> values for these two molecules are quite high, with reported values ranging between 50 and 300 µM in nuclear extract and between 1 and 10 mM in whole cells (<xref ref-type="bibr" rid="bib50">Huber et al., 2011</xref>; <xref ref-type="bibr" rid="bib100">Silva et al., 2018</xref>; <xref ref-type="bibr" rid="bib111">Vinolo et al., 2011</xref>; <xref ref-type="bibr" rid="bib113">Waldecker et al., 2008</xref>). While it is possible to reach those concentrations in the gut lumen or portal vein, few other organs would normally reach these values. In addition, our previous data suggests that SCFAs can induce histone hyperacetylation in colon, liver, and adipose tissue, which experience SCFA concentrations that differ by orders of magnitude (<xref ref-type="bibr" rid="bib64">Krautkramer et al., 2016</xref>). Even in the gut, intracellular concentrations of SCFAs could be significantly lower than exterior concentrations (<xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>; <xref ref-type="bibr" rid="bib97">Sengupta et al., 2006</xref>). Thus, the idea that increased histone acetylation is primarily mediated by HDAC inhibition requires re-evaluation.</p><p>In this study, we report a previously unappreciated mechanism and provide compelling evidence that butyrate and propionate activate p300 at low levels, through the rapid conversion to propionyl- and butyryl-CoA, catalytic auto-acylation, and subsequent activation of p300. While the IC<sub>50</sub> values for HDAC inhibition are in the high µM to mM range, K<sub>m</sub> values for p300 auto-acetylation lie in the nM to low µM range (<xref ref-type="bibr" rid="bib55">Karanam et al., 2006</xref>; <xref ref-type="bibr" rid="bib71">Liu et al., 2008</xref>). Hyperacetylation induced by high doses of butyrate (2–5 mM) are almost immediately reversed after butyrate withdrawal (<xref ref-type="bibr" rid="bib85">Prasad and Sinha, 1976</xref>; <xref ref-type="bibr" rid="bib114">Wang et al., 2018</xref>). In contrast, auto-acetylation of p300 increases its half-life from 4.5 to &gt;24 hr (<xref ref-type="bibr" rid="bib52">Jain et al., 2012</xref>). Thus, even after extracellular SCFAs have been fully metabolized, modified p300 could still theoretically induce hyperacetylation. Auto-acylation of p300 may thus prove a primary mechanism in physiological systems where SCFA concentrations are low.</p><p>It is important to note that acetate had negligible effect on histone acetylation in the cell-based systems described in this study. Acetate treatment has been previously reported to increase histone acetylation, but only under extreme conditions such as hypoxia (<xref ref-type="bibr" rid="bib15">Bulusu et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Gao et al., 2016</xref>), or after genetic manipulation (<xref ref-type="bibr" rid="bib120">Zhao et al., 2016</xref>). Others have reported no effect of acetate in conditions similar to those described here (<xref ref-type="bibr" rid="bib48">Hinnebusch et al., 2002</xref>). This phenomenon has traditionally been explained by the fact that acetate is a worse HDAC inhibitor than other SCFAs (<xref ref-type="bibr" rid="bib48">Hinnebusch et al., 2002</xref>; <xref ref-type="bibr" rid="bib113">Waldecker et al., 2008</xref>). Based on the results reported here, acetate’s lack of effect can be explained by the fact that acetate is not rapidly metabolized to acetyl-CoA, as propionate and butyrate are to their respective acyl-CoAs. It has been previously shown that extracellular acetate concentration does not necessarily correlate with intracellular concentrations of acetyl-CoA. Instead, under normal conditions, acetyl-CoA is mainly generated in the mitochondria from glucose (<xref ref-type="bibr" rid="bib115">Wellen et al., 2009</xref>). Since there is no evidence to date of acetyl-CoA crossing the mitochondrial membrane, acetyl-CoA must be shuttled to the cytosol via citrate. Once in the cytosol, citrate is converted into oxaloacetate and acetyl-CoA by ATP citrate lyase (ACLY). However, stress conditions such as hypoxia, or genetic knockout of ACLY, can cause the cell to rely on acetate for acetyl-CoA production (<xref ref-type="bibr" rid="bib15">Bulusu et al., 2017</xref>; <xref ref-type="bibr" rid="bib40">Gao et al., 2016</xref>; <xref ref-type="bibr" rid="bib120">Zhao et al., 2016</xref>). We do not expect these conditions to exist in the experiments described here.</p><p>The main pathways responsible for butyryl- and propionyl-CoA synthesis in the nucleus and cytoplasm are still unclear (<xref ref-type="bibr" rid="bib27">Corfe, 2012</xref>; <xref ref-type="bibr" rid="bib38">Fujino et al., 2001</xref>; <xref ref-type="bibr" rid="bib75">Luong et al., 2000</xref>; <xref ref-type="bibr" rid="bib108">Trefely et al., 2020</xref>). However, our results suggest that p300 auto-acylation and activation via SCFAs depend on robust cellular synthesis of the corresponding acyl-CoAs. In vivo, synthesis of acyl-CoAs may depend on complex interactions between various SCFAs. While we investigated each SCFA individually, it is possible that mixtures of each SCFA could have varied effects on histone acetylation. However, there is some data to suggest that in cells treated with mixtures of SCFAs, acetylation increased based only on the sum of butyrate and propionate concentrations (<xref ref-type="bibr" rid="bib60">Kiefer et al., 2006</xref>). This is consistent with our observation that the use of normal or dialyzed fetal bovine serum (FBS) in cell culture media did not affect the histone hyperacetylation phenotype (dialyzed FBS does not contain acetate). We predict that rapid histone acetylation, as described for the mechanism revealed in this study, will depend on the ability of cells to convert each SCFA to its corresponding acyl-CoA.</p><p>The p300 activation mechanism revealed here could also resolve outstanding issues. SCFA treatment phenocopies other HDAC inhibitors in some cases (<xref ref-type="bibr" rid="bib20">Chang et al., 2014</xref>; <xref ref-type="bibr" rid="bib87">Rahman et al., 2003</xref>; <xref ref-type="bibr" rid="bib123">Zhou et al., 2011</xref>), but not others (<xref ref-type="bibr" rid="bib78">Milton et al., 2012</xref>; <xref ref-type="bibr" rid="bib98">Siavoshian et al., 2000</xref>; <xref ref-type="bibr" rid="bib122">Zhao et al., 2020b</xref>). An alternate method for SCFAs to regulate histone acetylation could account for some of these discrepancies. In addition, several groups have reported that certain phosphatase or PKC inhibitors can reverse SCFA-induced hyperacetylation (<xref ref-type="bibr" rid="bib28">Cuisset et al., 1997</xref>; <xref ref-type="bibr" rid="bib29">Cuisset et al., 1998</xref>; <xref ref-type="bibr" rid="bib89">Rickard et al., 1999</xref>). While it has been proposed that this is due to phosphorylation of HDACs (<xref ref-type="bibr" rid="bib33">Davie, 2003</xref>), it is interesting to note that these inhibitors are also known to interact with p300 (H.-H. <xref ref-type="bibr" rid="bib23">Cheng et al., 2014</xref>; <xref ref-type="bibr" rid="bib44">Granja et al., 2008</xref>; <xref ref-type="bibr" rid="bib119">Zgheib et al., 2012</xref>).</p><p>Our proposed mechanism also raises the question: why is p300 specifically activated after SCFA treatment? Many HATs can acylate histones, and some are even known to auto-acetylate (<xref ref-type="bibr" rid="bib54">Kaczmarska et al., 2017</xref>; <xref ref-type="bibr" rid="bib67">Leemhuis et al., 2008</xref>; <xref ref-type="bibr" rid="bib117">Yang et al., 2012</xref>). In general, rates of acylation decrease as acyl chains increase, to the extent that butyryl-CoA can act as a competitive inhibitor for some HATs (<xref ref-type="bibr" rid="bib17">Carrer et al., 2017</xref>; <xref ref-type="bibr" rid="bib79">Montgomery et al., 2015</xref>; <xref ref-type="bibr" rid="bib90">Ringel and Wolberger, 2016</xref>; <xref ref-type="bibr" rid="bib101">Simithy et al., 2017</xref>). Thus, a sharp increase in acyl-CoA concentrations could slow most HATs, which cannot efficiently use longer acyl-CoAs as substrates. Intriguingly, previous reports indicate that p300 is also less efficient at histone propionylation and butyrylation than it is at histone acetylation (<xref ref-type="bibr" rid="bib54">Kaczmarska et al., 2017</xref>), which is consistent with our histone PTM analyses (<xref ref-type="fig" rid="fig1">Figure 1</xref>). However, our measured rates of p300 auto-acylation were indistinguishable between acetate, propionate, and butyrate. In addition, the reported K<sub>m</sub> of p300 for auto-acetylation (~100 nM) is lower than for acetylation of histone substrates (~6 µM) (<xref ref-type="bibr" rid="bib55">Karanam et al., 2006</xref>; <xref ref-type="bibr" rid="bib71">Liu et al., 2008</xref>). While the differences between the catalytic mechanisms for p300 auto-acylation and histone acylation have not yet been elucidated, this data suggests that p300 may have different substrate preferences for these two reactions. Thus, p300 may prefer to use acyl-CoAs to auto-acylate, which would activate the enzyme toward other substrates targeted for acetylation. In that case, while higher concentrations of acyl-CoAs may slow or inhibit other HATs, they could preferentially activate p300 via auto-acylation. The fact that our proteomics data shows more robust increases in histone acetylation than histone propionylation or butyrylation would further support this hypothesis (<xref ref-type="fig" rid="fig1">Figure 1</xref>).</p><p>It should be noted that SCFAs are also known to bind and activate several G-protein coupled receptors (GPCRs), especially FFAR2, FFAR3, and HCAR2 (<xref ref-type="bibr" rid="bib14">Brown et al., 2003</xref>; <xref ref-type="bibr" rid="bib51">Inoue et al., 2014</xref>; <xref ref-type="bibr" rid="bib86">Priyadarshini et al., 2018</xref>; <xref ref-type="bibr" rid="bib102">Singh et al., 2014</xref>; <xref ref-type="bibr" rid="bib105">Thangaraju et al., 2009</xref>; <xref ref-type="bibr" rid="bib116">Xiong et al., 2004</xref>). These receptors are not expressed in most of the cell lines investigated here, and do not influence the hyperacetylation phenotype when they are (<xref ref-type="fig" rid="fig1">Figure 1C</xref>). However, exploring the potential interactions between GPCR activation and histone hyperacetylation will be critical to a full understanding of SCFA signaling and metabolism, and its impact on human health.</p><p>Finally, we are not suggesting that SCFAs cannot induce HDAC inhibition under certain physiological conditions. Butyrate especially is likely capable of inducing HDAC inhibition in the colon, where extracellular concentrations of butyrate are often &gt;10 mM. In fact, this may be the reason that butyrate leads to higher levels of histone acetylation than propionate at the 1 mM treatment concentration (<xref ref-type="fig" rid="fig1">Figure 1</xref>), but not at the 100 µM treatment concentration (<xref ref-type="fig" rid="fig4">Figure 4</xref>). Discovering which mechanism is most prevalent at various concentrations may assist in understanding the pharmacology of this crucial molecule.</p><p>The results presented in this study provide key new insight into the actions of normal physiological and therapeutic levels of SCFAs. This is especially important in the case of butyrate, which is the subject of over 100 active clinical trials. In fact, there is already evidence that low SCFA concentrations can have widely different physiological effects while still increasing histone acetylation (<xref ref-type="bibr" rid="bib8">Biermann et al., 2011</xref>; <xref ref-type="bibr" rid="bib35">Donohoe et al., 2012</xref>). By comparing cellular responses to high and low SCFA doses (e.g., 5 mM and 50 µM), it may be possible to explore distinct cellular responses given the different mechanisms. It may also be necessary to reexamine the systemic effects of SCFAs. Many studies use high doses of SCFAs (5–30 mM), even in regions of the body where physiological concentrations should be thousands of times lower. It is possible that these doses are not necessary to induce hyperacetylation and could in fact obscure biologically relevant pathways. In the end, this new data suggest that the mechanism of action extends beyond HDAC inhibition and should be incorporated into the rationale for the therapeutic use of SCFAs.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><tbody><tr><td align="left" valign="bottom"><bold>Reagent type (species) or resource</bold></td><td align="left" valign="bottom"><bold>Designation</bold></td><td align="left" valign="bottom"><bold>Source or reference</bold></td><td align="left" valign="bottom"><bold>Identifiers</bold></td><td align="left" valign="bottom"><bold>Additional information</bold></td></tr><tr><td align="left" valign="bottom">HCT116 cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">Colorectal carcinoma</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CCL-247</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0291">CVCL_0291</ext-link></td></tr><tr><td align="left" valign="bottom">HEK-293 cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">Kidney epithelial</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">CRL-1573</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0045">CVCL_0045</ext-link></td></tr><tr><td align="left" valign="bottom">HepG2 cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">Liver epithelial</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HB-8065</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0027">CVCL_0027</ext-link></td></tr><tr><td align="left" valign="bottom">MCF7 cell line (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">Adenocarcinoma epithelial</td><td align="left" valign="bottom">ATCC</td><td align="left" valign="bottom">HTB-22</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_0031">CVCL_0031</ext-link></td></tr><tr><td align="left" valign="bottom">PCCA mutant cell lines (<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">Propionic acidemia cell lines</td><td align="left" valign="bottom">NIGMS Human Genetic Cell Repository, Coriell Institute</td><td align="left" valign="bottom">GM00371 GM00405 GM22010 GM22011 GM22123 GM22126</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to ACSS2 (SMARTpool)</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">L-010396-00-0005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to ACLY (SMARTpool)</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">L-004915-00-0005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">siRNA to PCCA (SMARTpool)</td><td align="left" valign="bottom">Dharmacon</td><td align="left" valign="bottom">L-008965-00-0005</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Transfected construct (human)</td><td align="left" valign="bottom">p300 mutant constructs</td><td align="left" valign="bottom">Ortega et. al. 2018</td><td align="left" valign="bottom">WT p300, ΔGlu p300</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">ACLY, rabbit</td><td align="left" valign="bottom">CST</td><td align="char" char="." valign="bottom">4,332 S</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2223744">AB_2223744</ext-link>, 1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">ACSS2, mouse</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">NBP2-01269</td><td align="char" char="." valign="bottom">1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">FFAR2/GPR43, mouse</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">MAB10082-100</td><td align="char" char="." valign="bottom">1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">FFAR3/GPR41, rabbit</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">NBP2-14014</td><td align="char" char="." valign="bottom">1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">H3, mouse</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab24834</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_470335">AB_470335</ext-link>, 1:5,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">H3 K18ac, rabbit</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">ab1191</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_298692">AB_298692</ext-link>, 1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">H3 K27ac, mouse</td><td align="left" valign="bottom">Active Motif</td><td align="char" char="." valign="bottom">39,685</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2793305">AB_2793305</ext-link>, 1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">HA-Tag, rabbit</td><td align="left" valign="bottom">CST</td><td align="char" char="." valign="bottom">3,724</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1549585">AB_1549585</ext-link>, 1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">p300 (NM11), mouse</td><td align="left" valign="bottom">SCBT</td><td align="left" valign="bottom">sc-32244</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_628076">AB_628076</ext-link>, 1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">p53, mouse</td><td align="left" valign="bottom">CST</td><td align="char" char="." valign="bottom">2,524</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_331743">AB_331743</ext-link>, 1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">p53 K382ac, rabbit</td><td align="left" valign="bottom">CST</td><td align="char" char="." valign="bottom">2,525</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_330083">AB_330083</ext-link>, 1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Pan anti-acetyllysine, rabbit</td><td align="left" valign="bottom">CST</td><td align="char" char="." valign="bottom">9,814</td><td align="char" char="." valign="bottom">1:1,000 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Pan anti-butyryllysine, mouse</td><td align="left" valign="bottom">PTM Biolabs</td><td align="left" valign="bottom">PTM-329</td><td align="char" char="." valign="bottom">1:500 dilution</td></tr><tr><td align="left" valign="bottom">antibody</td><td align="left" valign="bottom">Pan anti-propionyllysine, rabbit</td><td align="left" valign="bottom">PTM Biolabs</td><td align="left" valign="bottom">PTM-201</td><td align="char" char="." valign="bottom">1:500 dilution</td></tr></tbody></table></table-wrap><sec id="s4-1"><title>Materials</title><p>Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). All reagents used for proteomic and metabolomic samples were HPLC-grade. All cell lines were regularly tested for mycoplasma contamination.</p></sec><sec id="s4-2"><title>SCFA cell line treatments</title><p>All cell lines were plated in Minimum Essential Media (MEM) supplemented with 10% dialyzed FBS the day before SCFA treatment. MEM contains ~5 mM glucose, compared to ~25 mM in Dulbecco's modified Eagle's medium. Stock solutions of each SCFA were prepared fresh in PBS the day of each experiment. After collection, cell pellets and metabolite extracts were stored at –80°C. Using preliminary data sets to estimate population variance, a minimum of three biological replicates are necessary to detect changes of 50% or greater, assuming α=0.05 and power=0.80. We thus chose 3–4 replicates for all experiments unless otherwise noted.</p><sec id="s4-2-1"><title>Histone proteomics</title><p>We performed histone proteomics as described previously (<xref ref-type="bibr" rid="bib64">Krautkramer et al., 2016</xref>; <xref ref-type="bibr" rid="bib99">Sidoli et al., 2016</xref>). The method is briefly described below.</p></sec><sec id="s4-2-2"><title>Histone extraction and derivatization</title><p>Cells were trypsinized and washed once with PBS. Cell pellets were then dounce homogenized in lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, and pH 7.4)+ protease inhibitors (10 mM nicotinamide, 1 mM sodium butyrate, 4 µM trichostatin A, 10 µg/ml leupeptin, 10 µg/ml aprotinin, and 100 µM PMSF) and nuclei were spun out. Histones were extracted from the nuclei pellet with 0.4 N H<sub>2</sub>SO<sub>4</sub> for 4 hr. Extracted histones were then TCA precipitated overnight and washed with acetone. After performing a Bradford assay to determine protein concentrations, 5 µg of each sample was dried down and resuspended in 100 mM triethylammonium bicarbonate buffer. Unmodified lysines were labeled with d<sub>6</sub>-acetic anhydride, a labeling method that allows for quantification of histone acylations (<xref ref-type="bibr" rid="bib106">Thomas et al., 2020</xref>). Labeled histones were digested with trypsin and labeled with N-termini phenyl isocyanate before stage tip desalting and resuspension sample diluent (5% ACN, 0.1% acetic acid in H<sub>2</sub>O).</p></sec><sec id="s4-2-3"><title>UPLC MS/MS analysis</title><p>Derivatized histone peptide was injected onto a Dionex Ultimate3000 nanoflow HPLC with a Waters nanoAcquity UPLC C18 column (100 m × 150 mm, 3 m) coupled to a Thermo Fisher Q-Exactive mass spectrometer at 700 nl/min. Mobile phase consisted of water +0.1% formic acid (A) and acetonitrile +0.1% formic acid (B). Histone peptides were resolved with a two-step linear gradient of 5–35% B over 45 min followed by 35–95% B over 10 min. Data was acquired in data-independent acquisition (DIA) mode. The MS1 scan resolution=35,000, automatic gain control target=1 ×10<sup>6</sup>, and scan range=390–910 <italic>m/z</italic>, followed by a DIA scan with a loop count of 10. DIA settings: window size=10 <italic>m/z</italic>, resolution=17,500, automatic gain control target=1 ×10<sup>6</sup>, DIA maximum fill time=Auto, and normalized collision energy=30. For each cycle, 1 full MS1 scan was followed by 10 MS2 scans using an isolation window size of 10 <italic>m/z</italic>.</p></sec><sec id="s4-2-4"><title>Data analysis</title><p>Thermo RAW files were loaded into EpiProfile 2.0 and run using the AcD3 module (<xref ref-type="bibr" rid="bib118">Yuan et al., 2018</xref>). Normalization and statistics were then performed using our previously published Histone Analysis Workflow (<xref ref-type="bibr" rid="bib106">Thomas et al., 2020</xref>). RAW files, peak tables, and processing scripts have been uploaded to the MassIVE database and can be accessed with username: MSV000087800_reviewer and password: SCFAp300.</p></sec></sec><sec id="s4-3"><title>Metabolomics</title><sec id="s4-3-1"><title>Sample preparation</title><p>Cells were plated in six-well plates and allowed to reach ~70% confluency. Media was replaced with fresh media 1 hr before the experiment, and then again with media+SCFAs at time 0. Extraction and derivatization solutions were also prepared at least 1 hr before the experiment and stored at –20°C. Extraction solution contained 80:20 methanol:water with 1:2500 dilution of a heavy amino acid mix standard (MSK-A2, Cambridge Isotope Laboratories); derivatization solution is described below. At each time point, media was collected for SCFA measurements (see below) and cells were washed 3× with 0.9% NaCl. Then, 700 µl of ice-cold extraction solution was added and plates were set at –80°C for 15 min. After 15 min, cells were scraped into extraction solution and aliquots were taken for SCFA measurement and DNA quantification. The rest was spun down at max speed for 5 min at 4°C. The resulting supernatant was split in two and dried down using a speed vac and stored at –80°C. Samples were reconstituted in ice-cold 50 mM ammonium acetate and spun down again before injection into the mass spec. One half of the sample was run in positive mode, while the other half was run in negative mode (details below). Samples were reconstituted in batches and run in random order to minimize error due to metabolite decay or instrumentation.</p><p>SCFA concentrations were measured by LC-MS using the derivatization protocol described by <xref ref-type="bibr" rid="bib74">Lu et al., 2013</xref>. In brief, 10 µl of media or cell extract was added to 150 µl of derivatization solution containing 0.5 mM of 2-hydrazinoquinoline, triphenylphosphine, 2,2′dipyridyl disulfide, and either 250 µM (for media) or 25 µM (for cells) unlabeled acetate, propionate, and butyrate. Samples were incubated at 60°C for 1 hr and then spun at max speed for 5 min to remove any cellular debris. The resulting supernatant was mixed 1:1 with ice-cold 50 mM ammonium acetate before injection.</p><p>To measure cellular concentration, we used the Hoechst staining protocol described by <xref ref-type="bibr" rid="bib81">Muschet et al., 2016</xref>. To do so, 20 µl of metabolite extract was added to 80 µl of Hoechst 33342 (CST) diluted to 20 µg/ml in ddH<sub>2</sub>O. Samples were incubated in the dark for 30 min in a black 96-well plate and then read on a plate reader with Ex/Em=355/465 nm. Samples were compared to a dose curve of known cell numbers.</p></sec><sec id="s4-3-2"><title>UPLC MS/MS analysis</title><p>All metabolites were injected onto a Dionex Ultimate3000 nanoflow HPLC with a Waters ACQUITY UPLC BEH C18 column (2.1 mm×100 mm) coupled to a Thermo Fisher Q-Exactive mass spectrometer at 0.2 ml/min. Separate columns were used for positive and negative mode to reduce TBA contamination. For samples run in positive mode, mobile phase consisted of water +5 mM ammonium acetate +0.05% acetic acid (A) and 90% acetonitrile +5 mM ammonium acetate +0.05% acetic acid (B). Positive mode metabolites were resolved with a two-step linear gradient of 2–85% B over 5 min followed by 85–95% B over 6 min. For derivatized samples, data was acquired in data-dependent acquisition (DDA) mode. MS1 scan resolution=140,000, automatic gain control target=3×10<sup>6</sup>, and scan range=189–450 <italic>m/z</italic>. MS2 scan resolution=35,000, automatic gain control target=1× 10<sup>5</sup>, loop count=5, and isolation window=4.0 <italic>m/z</italic>. For other positive mode samples, only MS1 data was acquired in two isolation windows from 60 to 184 <italic>m/z</italic> and 189 to 1200 <italic>m/z</italic>. MS1 scan resolution=70,000, automatic gain control target=1× 10<sup>6</sup>.</p><p>For samples run in negative mode, mobile phase consisted of methanol (A) and water +3% methanol +10 mM tributylamine +0.05% acetic acid (B). Metabolites were resolved with a linear gradient of 95–5% B over 15 min. Only MS1 data was acquired. Scan resolution=70,000, automatic gain control target=1×10<sup>6</sup>, and scan range=59–880 <italic>m/z</italic>.</p></sec><sec id="s4-3-3"><title>Data analysis</title><p>Metabolite identification and peak integration were performed in EL-MAVEN (Elucidata). For SCFA concentrations, heavy SCFAs were normalized to unlabeled internal controls and SCFA dose curves run throughout the course of the experiment. For all other metabolites, data was normalized to heavy amino acid standards and cell number determined by Hoechst stain. All <sup>13</sup>C-labeling was corrected based on natural <sup>13</sup>C abundance.</p></sec></sec><sec id="s4-4"><title>ACLY, ACSS2, and PCC knockdowns</title><p>HCT116 cells were transfected with siRNA SMARTpools targeting ACLY, ACSS2, and PCC according to the manufacturer’s protocols. In short, 10 nM ACLY, ACSS2, and non-targeting siRNAs and 20 nM PCC siRNA were transfected using Lipofectamine RNAiMAX and opti-MEM media and allowed to incubate for 48 hr. Media was then replaced with fresh MEM media containing 1 mM SCFA and incubated for 1 hr. Knockdown efficiency was assessed by Western blotting.</p><p>Primary lymphoblasts from patients with propionic acidemia and family matched controls were purchased from the NIGMS Human Genetic Cell Repository. Propionic acidemia is a rare genetic disease caused by mutations in PCC. Knockout of PCC activity was confirmed using the HPLC assay developed by Y.-N. <xref ref-type="bibr" rid="bib72">Liu et al., 2016</xref>. Since lymphoblasts are grown in suspension, stock solutions of SCFA were added directly to media, resulting in 1 mM final concentrations. Cells were treated with SCFAs for 4 hr before collection.</p></sec><sec id="s4-5"><title>HDAC assay</title><p>HDAC activity of HCT116 nuclear extract was assayed using the Fluorometric HDAC Activity Assay Kit from Abcam (ab156064) according to the manufacturer’s protocol. Briefly, nuclear extract was prepared by dounce homogenizing cell pellets in lysis buffer (10 mM Tris-HCl, 10 mM NaCl, 3 mM MgCl<sub>2</sub>, and pH 7.4), then spinning out nuclei and resuspending in nuclear extraction buffer (50 mM HEPES, 420 mM NaCl, 0.5 mM EDTA, 0.1 mM EGTA, 10% glycerol, and pH 7.5). Protein concentration was determined by Bradford, and then 50 µg was added to dose curves of butyrate, propionate, and their corresponding acyl-CoAs. TSA was used as a positive control. Fluorescence signal (Ex/Em=360/450 nm) was read on a plate reader at 2 min intervals for 1 hr. Values were averaged over two technical replicates. IC<sub>50</sub> values were calculated using GraphPad Prism.</p></sec><sec id="s4-6"><title>HAT assays</title><sec id="s4-6-1"><title>Colorimetric assay</title><p>HAT activity was assayed using the HAT Activity Assay Kit from Sigma-Aldrich (EPI001), which measures release of free CoA over time. Acetyl-CoA levels were kept constant at 100 µM. Nuclear extract was the same as that used in the HDAC assay. 50 µg nuclear extract was added to kit components and dose curves of butyrate, propionate, and corresponding acyl-CoAs. Signal at 440 nm was read on a plate reader at 2 min2-min intervals for 2 hr. Values are averaged over two technical replicates.</p></sec><sec id="s4-6-2"><title><italic>Recombinant p300</italic>—</title><p>Recombinant catalytic domain of p300 was purchased from Enzo Life Sciences (BML-SE451). To remove endogenous acetylation from the recombinant protein, p300 was incubated with mammalian SIRT2 and NAD. SIRT2 was kindly provided by Dr. Mark Klein. For each experiment, equimolar amounts of SIRT2 and p300 and a tenfold molar excess of NAD were incubated at RT for 45 min. This incubation reduced endogenous acetylation on p300 five- to tenfold without inhibiting auto-acylation (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>). Excess NAD was then removed by running protein over a Zeba Spin desalting column (Thermo Fisher Scientific). Acyl-CoAs were then added back to the enzyme and auto-acylation was allowed to continue at RT for 30–60 min. For untreated controls, the same amount of CoA was added to account for CoA concentration. Finally, for denatured samples, p300 was incubated with SIRT2 and then boiled at 95°C for 5 min before the addition of acyl-CoAs.</p></sec><sec id="s4-6-3"><title>Auto-acylation assay</title><p>Recombinant enzyme was treated with SIRT2, then diluted to 1 µM in HAT assay buffer (50 mM Bis-Tris, 25 mM Tris, 10 mM NaCl, and pH 7) with 80 µM acyl-CoA. For each time point, 2 µl of each sample was dotted directly onto nitrocellulose membrane. Membranes were then allowed to dry for 30 min before blocking and incubating with antibodies specific to each acyl-CoA.</p></sec><sec id="s4-6-4"><title>Identification of lysine acylation</title><p>Recombinant enzyme was prepared as described above, then dried down, resuspended in 100 mM triethylammonium bicarbonate buffer, and trypsinized overnight. Samples were then stage tip desalted and resuspended in sample diluent (same as histone protocol above). Samples were run on a Thermo Fisher Q-Exactive mass spectrometer using the same settings as histone samples, except that they were run in DDA rather than DIA mode. Acyl identification was performed using Mascot (Matrix Science) and manually validated in XCalibur (Thermo Fisher Scientific). Acylation had to be present in two of three samples to be reported.</p></sec><sec id="s4-6-5"><title><sup>3</sup>H acetylation assay</title><p>Tritiated acetyl-CoA was purchased from PerkinElmer. For each assay, reaction buffer was made by using HAT assay buffer with 5 µM cold acetyl-CoA, 1 µM hot acetyl-CoA, and 25 µM biotinylated peptide. Biotinylated peptide was kindly provided by Dr. Vyacheslav Kuznetsov and corresponds to resides 9–23 of histone H3. Reactions were started by addition of 24 µl reaction buffer to 2 µl acetylated p300 (final concentration 10 nM). At each time point, 7 µl of the reaction mixture was added to 150 µl of cold 2% TFA +5% Streptavidin Sepharose High Performance (v/v, Cytiva). After the time course was completed, samples were incubated at RT with shaking for 30 min. The samples were then spun down at 1000×<italic>g</italic> for 1 min, and then washed with 2 ml of 10% acetone. The washed sepharose was then directly added to 2 ml Ultima Gold scintillation cocktail (PerkinElmer). Radioactivity was read by a Tri-Carb 2910TR scintillation counter (PerkinElmer). The scintillation counter was calibrated before each run.</p></sec><sec id="s4-6-6"><title>Western HAT assays</title><p>For western samples, 100 nM acylated p300 was added to a master mix of 100 µl acetyl-CoA and 0.4 µg/µl histone H3/H4 dimers. Samples were collected by adding 20 µl directly to 5 µl of 4× sample loading buffer (LI-COR) and heating at 95°C for 5 min. Samples were run on Bolt 4–12% Bis-Tris gels using the XCell II blot module (Thermo Fisher Scientific). Protein was transferred onto nitrocellulose membranes for 45 min and then allowed to block in 5% BSA for 1 hr. Samples were incubated in primary antibody overnight, before washing and incubating in LI-COR secondary antibody for 1 hr. All membranes were imaged on a LI-COR Odyssey imager and quantified using ImageStudio (LI-COR). Whenever possible, antibodies for modifications and loading controls were run simultaneously using two separate fluorescent LI-COR channels. <italic>p300 transfections</italic>—p300 plasmids were a kind gift from Dr. Daniel Panne (<xref ref-type="bibr" rid="bib82">Ortega et al., 2018</xref>) HCT116 cells were grown to ~60% confluency and transfected with Lipofectamine 3000 according to the manufacturer’s protocols. After 48 hr, media was replaced with MEM media containing 500 µg/ml Geneticin (Thermo Fisher Scientific). Antibiotic media was then replaced every 2 days for 1 week to select for transfected cells. After 1 week, cells were treated with 500 µM propionate for 2 hr. Samples were collected as described previously. HA and p300 blots were performed as described in the previous section, except that transfers were allowed to run overnight to maximize signal for high molecular weight proteins. <italic>p300 immunoprecipitation</italic>—HCT116 cells were grown to 60–70% confluency and treated with 500 µM propionate or butyrate for 1 hr. Cells were lysed using RIPA buffer and Pierce protease phosphatase inhibitors (Thermo Fisher Scientific). Protein concentrations were determined by Bradford assay and equal amounts of protein were added to a slurry of Dynabeads Protein G (Thermo Fisher Scientific) and p300 antibody (NM11, Santa Cruz Biotechnology). Samples were allowed to incubate 3 hr at 4°C before washing twice with Tris buffer +0.01 Triton. Washed beads were then directly added to radioactive assays or run on gels as described previously. For radioactive assays, beads were incubated with 1 µM hot acetyl-CoA and 25 µM biotinylated peptide for 1 hr before quenching reaction in 2% TFA +5% Streptavidin Sepharose High Performance (v/v, Cytiva).</p></sec></sec></sec></body><back><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – original draft, Writing – review and editing, Software</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Investigation, Methodology, Project administration, Supervision, Visualization, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="pdf" mimetype="application" xlink:href="elife-72171-transrepform1-v2.pdf"/></supplementary-material><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Raw Data and Replicates for Enzyme Assays.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-72171-supp1-v2.xlsx"/></supplementary-material><supplementary-material id="sdata2"><label>Source data 2.</label><caption><title>Full Western Blots and Replicate Blots.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-72171-supp2-v2.zip"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>Mass spectrometry data has been uploaded to MassIVE (MSV000087800). All other source data is included in Source Data 1 and 2.</p><p>The following dataset was generated:</p><p><element-citation id="dataset1" publication-type="data" specific-use="isSupplementedBy"><person-group person-group-type="author"><name><surname>Denu</surname><given-names>J</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Data for: Short-chain fatty acids activate acetyltransferase p300/CBP</data-title><source>MassIVE</source><pub-id pub-id-type="accession" xlink:href="ftp://massive.ucsd.edu/MSV000087800/">MSV000087800</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>p300 plasmids were a kind gift from Dr. Daniel Panne, Leicester Institute of Structural and Chemical Biology, UK. Pan-butyryl antibody was the kind gift of Dr. Yingming Zhao, University of Chicago, USA. Recombinant SIRT2 was kindly provided by Dr. Mark Klein. H3 and H4 proteins and peptides were kindly provided by Dr. Vyacheslav Kuznetsov, Dr. Wallace Liu, and Lily Miller. The authors thank Dr. James Dowell and Eric Armstrong for their helpful discussions of mass spec analysis. The authors also thank Dr. Mark Klein, José Moran, and Dr. Spencer Haws for their helpful discussions of HAT assays. J.M.D. is co-founder of Galilei Biosciences and a member of the scientific advisory board for Evrys Bio.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abdelli</surname><given-names>LS</given-names></name><name><surname>Samsam</surname><given-names>A</given-names></name><name><surname>Naser</surname><given-names>SA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Propionic Acid Induces Gliosis and Neuro-inflammation through Modulation of PTEN/AKT Pathway in Autism Spectrum Disorder</article-title><source>Scientific Reports</source><volume>9</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-45348-z</pub-id><pub-id pub-id-type="pmid">31217543</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Lahham</surname><given-names>SH</given-names></name><name><surname>Peppelenbosch</surname><given-names>MP</given-names></name><name><surname>Roelofsen</surname><given-names>H</given-names></name><name><surname>Vonk</surname><given-names>RJ</given-names></name><name><surname>Venema</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Biological effects of propionic acid in humans; metabolism, potential applications and underlying mechanisms</article-title><source>Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids</source><volume>1801</volume><fpage>1175</fpage><lpage>1183</lpage><pub-id pub-id-type="doi">10.1016/J.BBALIP.2010.07.007</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albaugh</surname><given-names>BN</given-names></name><name><surname>Arnold</surname><given-names>KM</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>KAT(ching) metabolism by the tail: Insight into the links between lysine acetyltransferases and metabolism</article-title><source>Chembiochem</source><volume>12</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="doi">10.1002/cbic.201000438</pub-id><pub-id pub-id-type="pmid">21243716</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bannister</surname><given-names>AJ</given-names></name><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Regulation of chromatin by histone modifications</article-title><source>Cell Research</source><volume>21</volume><fpage>381</fpage><lpage>395</lpage><pub-id pub-id-type="doi">10.1038/cr.2011.22</pub-id><pub-id pub-id-type="pmid">21321607</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Basu</surname><given-names>SS</given-names></name><name><surname>Mesaros</surname><given-names>C</given-names></name><name><surname>Gelhaus</surname><given-names>SL</given-names></name><name><surname>Blair</surname><given-names>IA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Stable Isotope Labeling by Essential Nutrients in Cell Culture for Preparation of Labeled Coenzyme A and Its Thioesters</article-title><source>Analytical Chemistry</source><volume>83</volume><fpage>1363</fpage><lpage>1369</lpage><pub-id pub-id-type="doi">10.1021/ac1027353</pub-id><pub-id pub-id-type="pmid">21268609</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bergman</surname><given-names>EN</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Energy contributions of volatile fatty acids from the gastrointestinal tract in various species</article-title><source>Physiological Reviews</source><volume>70</volume><fpage>567</fpage><lpage>590</lpage><pub-id pub-id-type="doi">10.1152/physrev.1990.70.2.567</pub-id><pub-id pub-id-type="pmid">2181501</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berndsen</surname><given-names>CE</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Catalysis and Substrate Selection by Histone/Protein Lysine Acetyltransferases</article-title><source>Current Opinion in Structural Biology</source><volume>18</volume><fpage>682</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1016/j.sbi.2008.11.004</pub-id><pub-id pub-id-type="pmid">19056256</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biermann</surname><given-names>J</given-names></name><name><surname>Boyle</surname><given-names>J</given-names></name><name><surname>Pielen</surname><given-names>A</given-names></name><name><surname>Lagrèze</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Histone deacetylase inhibitors sodium butyrate and valproic acid delay spontaneous cell death in purified rat retinal ganglion cells</article-title><source>Molecular Vision</source><volume>17</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">21311741</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bird</surname><given-names>AR</given-names></name><name><surname>Hayakawa</surname><given-names>T</given-names></name><name><surname>Marsono</surname><given-names>Y</given-names></name><name><surname>Gooden</surname><given-names>JM</given-names></name><name><surname>Record</surname><given-names>IR</given-names></name><name><surname>Correll</surname><given-names>RL</given-names></name><name><surname>Topping</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Coarse brown rice increases fecal and large bowel short-chain fatty acids and starch but lowers calcium in the large bowel of pigs</article-title><source>The Journal of Nutrition</source><volume>130</volume><fpage>1780</fpage><lpage>1787</lpage><pub-id pub-id-type="doi">10.1093/jn/130.7.1780</pub-id><pub-id pub-id-type="pmid">10867050</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bloemen</surname><given-names>JG</given-names></name><name><surname>Venema</surname><given-names>K</given-names></name><name><surname>van de Poll</surname><given-names>MC</given-names></name><name><surname>Olde Damink</surname><given-names>SW</given-names></name><name><surname>Buurman</surname><given-names>WA</given-names></name><name><surname>Dejong</surname><given-names>CH</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Short chain fatty acids exchange across the gut and liver in humans measured at surgery</article-title><source>Clinical Nutrition</source><volume>28</volume><fpage>657</fpage><lpage>661</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2009.05.011</pub-id><pub-id pub-id-type="pmid">19523724</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boets</surname><given-names>E</given-names></name><name><surname>Gomand</surname><given-names>SV</given-names></name><name><surname>Deroover</surname><given-names>L</given-names></name><name><surname>Preston</surname><given-names>T</given-names></name><name><surname>Vermeulen</surname><given-names>K</given-names></name><name><surname>De Preter</surname><given-names>V</given-names></name><name><surname>Hamer</surname><given-names>HM</given-names></name><name><surname>Van den Mooter</surname><given-names>G</given-names></name><name><surname>De Vuyst</surname><given-names>L</given-names></name><name><surname>Courtin</surname><given-names>CM</given-names></name><name><surname>Annaert</surname><given-names>P</given-names></name><name><surname>Delcour</surname><given-names>JA</given-names></name><name><surname>Verbeke</surname><given-names>KA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Systemic availability and metabolism of colonic-derived short-chain fatty acids in healthy subjects: A stable isotope study</article-title><source>The Journal of Physiology</source><volume>595</volume><fpage>541</fpage><lpage>555</lpage><pub-id pub-id-type="doi">10.1113/JP272613</pub-id><pub-id pub-id-type="pmid">27510655</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bolduc</surname><given-names>JF</given-names></name><name><surname>Hany</surname><given-names>L</given-names></name><name><surname>Barat</surname><given-names>C</given-names></name><name><surname>Ouellet</surname><given-names>M</given-names></name><name><surname>Tremblay</surname><given-names>MJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Epigenetic Metabolite Acetate Inhibits Class I/II Histone Deacetylases, Promotes Histone Acetylation, and Increases HIV-1 Integration in CD4+ T Cells</article-title><source>Journal of Virology</source><volume>91</volume><fpage>e01943</fpage><lpage>e16</lpage><pub-id pub-id-type="doi">10.1128/JVI.01943-16</pub-id><pub-id pub-id-type="pmid">28539453</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bose</surname><given-names>S</given-names></name><name><surname>Ramesh</surname><given-names>V</given-names></name><name><surname>Locasale</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Acetate Metabolism in Physiology, Cancer, and Beyond</article-title><source>Trends in Cell Biology</source><volume>29</volume><fpage>695</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1016/j.tcb.2019.05.005</pub-id><pub-id pub-id-type="pmid">31160120</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>AJ</given-names></name><name><surname>Goldsworthy</surname><given-names>SM</given-names></name><name><surname>Barnes</surname><given-names>AA</given-names></name><name><surname>Eilert</surname><given-names>MM</given-names></name><name><surname>Tcheang</surname><given-names>L</given-names></name><name><surname>Daniels</surname><given-names>D</given-names></name><name><surname>Muir</surname><given-names>AI</given-names></name><name><surname>Wigglesworth</surname><given-names>MJ</given-names></name><name><surname>Kinghorn</surname><given-names>I</given-names></name><name><surname>Fraser</surname><given-names>NJ</given-names></name><name><surname>Pike</surname><given-names>NB</given-names></name><name><surname>Strum</surname><given-names>JC</given-names></name><name><surname>Steplewski</surname><given-names>KM</given-names></name><name><surname>Murdock</surname><given-names>PR</given-names></name><name><surname>Holder</surname><given-names>JC</given-names></name><name><surname>Marshall</surname><given-names>FH</given-names></name><name><surname>Szekeres</surname><given-names>PG</given-names></name><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Ignar</surname><given-names>DM</given-names></name><name><surname>Foord</surname><given-names>SM</given-names></name><name><surname>Wise</surname><given-names>A</given-names></name><name><surname>Dowell</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids</article-title><source>The Journal of Biological Chemistry</source><volume>278</volume><fpage>11312</fpage><lpage>11319</lpage><pub-id pub-id-type="doi">10.1074/jbc.M211609200</pub-id><pub-id pub-id-type="pmid">12496283</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bulusu</surname><given-names>V</given-names></name><name><surname>Tumanov</surname><given-names>S</given-names></name><name><surname>Michalopoulou</surname><given-names>E</given-names></name><name><surname>van den Broek</surname><given-names>NJ</given-names></name><name><surname>MacKay</surname><given-names>G</given-names></name><name><surname>Nixon</surname><given-names>C</given-names></name><name><surname>Dhayade</surname><given-names>S</given-names></name><name><surname>Schug</surname><given-names>ZT</given-names></name><name><surname>Vande Voorde</surname><given-names>J</given-names></name><name><surname>Blyth</surname><given-names>K</given-names></name><name><surname>Gottlieb</surname><given-names>E</given-names></name><name><surname>Vazquez</surname><given-names>A</given-names></name><name><surname>Kamphorst</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Acetate Recapturing by Nuclear Acetyl-CoA Synthetase 2 Prevents Loss of Histone Acetylation during Oxygen and Serum Limitation</article-title><source>Cell Reports</source><volume>18</volume><fpage>647</fpage><lpage>658</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.12.055</pub-id><pub-id pub-id-type="pmid">28099844</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Candido</surname><given-names>EPM</given-names></name><name><surname>Reeves</surname><given-names>R</given-names></name><name><surname>Davie</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="1978">1978</year><article-title>Sodium butyrate inhibits histone deacetylation in cultured cells</article-title><source>Cell</source><volume>14</volume><fpage>105</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1016/0092-8674(78)90305-7</pub-id><pub-id pub-id-type="pmid">667927</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carrer</surname><given-names>A</given-names></name><name><surname>Parris</surname><given-names>JLD</given-names></name><name><surname>Trefely</surname><given-names>S</given-names></name><name><surname>Henry</surname><given-names>RA</given-names></name><name><surname>Montgomery</surname><given-names>DC</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Viola</surname><given-names>JM</given-names></name><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Blair</surname><given-names>IA</given-names></name><name><surname>Meier</surname><given-names>JL</given-names></name><name><surname>Andrews</surname><given-names>AJ</given-names></name><name><surname>Snyder</surname><given-names>NW</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Impact of a High-fat Diet on Tissue Acyl-CoA and Histone Acetylation Levels</article-title><source>The Journal of Biological Chemistry</source><volume>292</volume><fpage>3312</fpage><lpage>3322</lpage><pub-id pub-id-type="doi">10.1074/jbc.M116.750620</pub-id><pub-id pub-id-type="pmid">28077572</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Caslini</surname><given-names>C</given-names></name><name><surname>Hong</surname><given-names>S</given-names></name><name><surname>Ban</surname><given-names>YJ</given-names></name><name><surname>Chen</surname><given-names>XS</given-names></name><name><surname>Ince</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>HDAC7 regulates histone 3 lysine 27 acetylation and transcriptional activity at super-enhancer-associated genes in breast cancer stem cells</article-title><source>Oncogene</source><volume>38</volume><fpage>6599</fpage><lpage>6614</lpage><pub-id pub-id-type="doi">10.1038/s41388-019-0897-0</pub-id><pub-id pub-id-type="pmid">31375747</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>HM</given-names></name><name><surname>La Thangue</surname><given-names>NB</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>p300/CBP proteins: HATs for transcriptional bridges and scaffolds</article-title><source>Journal of Cell Science</source><volume>114</volume><fpage>2363</fpage><lpage>2373</lpage><pub-id pub-id-type="pmid">11559745</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>PV</given-names></name><name><surname>Hao</surname><given-names>L</given-names></name><name><surname>Offermanns</surname><given-names>S</given-names></name><name><surname>Medzhitov</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>The microbial metabolite butyrate regulates intestinal macrophage function via histone deacetylase inhibition</article-title><source>PNAS</source><volume>111</volume><fpage>2247</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.1073/pnas.1322269111</pub-id><pub-id pub-id-type="pmid">24390544</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Sprung</surname><given-names>R</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Ball</surname><given-names>H</given-names></name><name><surname>Sangras</surname><given-names>B</given-names></name><name><surname>Kim</surname><given-names>SC</given-names></name><name><surname>Falck</surname><given-names>JR</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Lysine Propionylation and Butyrylation Are Novel Post-translational Modifications in Histones</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>6</volume><fpage>812</fpage><lpage>819</lpage><pub-id pub-id-type="doi">10.1074/mcp.M700021-MCP200</pub-id><pub-id pub-id-type="pmid">17267393</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Tang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>SSC</given-names></name><name><surname>Gu</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Molecular Characterization of Propionyllysines in Non-histone Proteins</article-title><source>Molecular &amp; Cellular Proteomics</source><volume>8</volume><fpage>45</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1074/mcp.M800224-MCP200</pub-id><pub-id pub-id-type="pmid">18753126</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>H-H</given-names></name><name><surname>Wang</surname><given-names>K-H</given-names></name><name><surname>Chu</surname><given-names>L</given-names></name><name><surname>Chang</surname><given-names>T-C</given-names></name><name><surname>Kuo</surname><given-names>C-C</given-names></name><name><surname>Wu</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Quiescent and Proliferative Fibroblasts Exhibit Differential p300 HAT Activation through Control of 5-Methoxytryptophan Production</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e88507</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0088507</pub-id><pub-id pub-id-type="pmid">24523905</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chriett</surname><given-names>S</given-names></name><name><surname>Dąbek</surname><given-names>A</given-names></name><name><surname>Wojtala</surname><given-names>M</given-names></name><name><surname>Vidal</surname><given-names>H</given-names></name><name><surname>Balcerczyk</surname><given-names>A</given-names></name><name><surname>Pirola</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Prominent action of butyrate over β-hydroxybutyrate as histone deacetylase inhibitor, transcriptional modulator and anti-inflammatory molecule</article-title><source>Scientific Reports</source><volume>9</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/s41598-018-36941-9</pub-id><pub-id pub-id-type="pmid">30679586</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausen</surname><given-names>MR</given-names></name><name><surname>Mortensen</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>Kinetic studies on the metabolism of short-chain fatty acids and glucose by isolated rat colonocytes</article-title><source>Gastroenterology</source><volume>106</volume><fpage>423</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/0016-5085(94)90601-7</pub-id><pub-id pub-id-type="pmid">8299908</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clausen</surname><given-names>MR</given-names></name><name><surname>Mortensen</surname><given-names>PB</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Kinetic studies on colonocyte metabolism of short chain fatty acids and glucose in ulcerative colitis</article-title><source>Gut</source><volume>37</volume><fpage>684</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1136/gut.37.5.684</pub-id><pub-id pub-id-type="pmid">8549946</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corfe</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Hypothesis: Butyrate is not an HDAC inhibitor, but a product inhibitor of deacetylation</article-title><source>Molecular BioSystems</source><volume>8</volume><fpage>1609</fpage><lpage>1612</lpage><pub-id pub-id-type="doi">10.1039/C2MB25028D</pub-id><pub-id pub-id-type="pmid">22446977</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuisset</surname><given-names>L</given-names></name><name><surname>Tichonicky</surname><given-names>L</given-names></name><name><surname>Jaffray</surname><given-names>P</given-names></name><name><surname>Delpech</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The effects of sodium butyrate on transcription are mediated through activation of a protein phosphatase</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>24148</fpage><lpage>24153</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.39.24148</pub-id><pub-id pub-id-type="pmid">9305863</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cuisset</surname><given-names>L</given-names></name><name><surname>Tichonicky</surname><given-names>L</given-names></name><name><surname>Delpech</surname><given-names>M</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A Protein Phosphatase Is Involved in the Inhibition of Histone Deacetylation by Sodium Butyrate</article-title><source>Biochemical and Biophysical Research Communications</source><volume>246</volume><fpage>760</fpage><lpage>764</lpage><pub-id pub-id-type="doi">10.1006/bbrc.1998.8698</pub-id><pub-id pub-id-type="pmid">9618285</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cummings</surname><given-names>JH</given-names></name><name><surname>Pomare</surname><given-names>EW</given-names></name><name><surname>Branch</surname><given-names>WJ</given-names></name><name><surname>Naylor</surname><given-names>CP</given-names></name><name><surname>Macfarlane</surname><given-names>GT</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Short chain fatty acids in human large intestine, portal, hepatic and venous blood</article-title><source>Gut</source><volume>28</volume><fpage>1221</fpage><lpage>1227</lpage><pub-id pub-id-type="doi">10.1136/gut.28.10.1221</pub-id><pub-id pub-id-type="pmid">3678950</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dai</surname><given-names>L</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Montellier</surname><given-names>E</given-names></name><name><surname>Lu</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Ishii</surname><given-names>H</given-names></name><name><surname>Debernardi</surname><given-names>A</given-names></name><name><surname>Buchou</surname><given-names>T</given-names></name><name><surname>Rousseaux</surname><given-names>S</given-names></name><name><surname>Jin</surname><given-names>F</given-names></name><name><surname>Sabari</surname><given-names>BR</given-names></name><name><surname>Deng</surname><given-names>Z</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name><name><surname>Ren</surname><given-names>B</given-names></name><name><surname>Khochbin</surname><given-names>S</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Lysine 2-hydroxyisobutyrylation is a widely distributed active histone mark</article-title><source>Nature Chemical Biology</source><volume>10</volume><fpage>365</fpage><lpage>370</lpage><pub-id pub-id-type="doi">10.1038/nchembio.1497</pub-id><pub-id pub-id-type="pmid">24681537</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dancy</surname><given-names>BM</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Protein Lysine Acetylation by p300/CBP</article-title><source>Chemical Reviews</source><volume>115</volume><fpage>2419</fpage><lpage>2452</lpage><pub-id pub-id-type="doi">10.1021/cr500452k</pub-id><pub-id pub-id-type="pmid">25594381</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davie</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Inhibition of histone deacetylase activity by butyrate</article-title><source>The Journal of Nutrition</source><volume>133</volume><fpage>2485S</fpage><lpage>2493S</lpage><pub-id pub-id-type="doi">10.1093/jn/133.7.2485S</pub-id><pub-id pub-id-type="pmid">12840228</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>den Besten</surname><given-names>G</given-names></name><name><surname>van Eunen</surname><given-names>K</given-names></name><name><surname>Groen</surname><given-names>AK</given-names></name><name><surname>Venema</surname><given-names>K</given-names></name><name><surname>Reijngoud</surname><given-names>DJ</given-names></name><name><surname>Bakker</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism</article-title><source>Journal of Lipid Research</source><volume>54</volume><fpage>2325</fpage><lpage>2340</lpage><pub-id pub-id-type="doi">10.1194/jlr.R036012</pub-id><pub-id pub-id-type="pmid">23821742</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donohoe</surname><given-names>DR</given-names></name><name><surname>Collins</surname><given-names>LB</given-names></name><name><surname>Wali</surname><given-names>A</given-names></name><name><surname>Bigler</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Bultman</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation</article-title><source>Molecular Cell</source><volume>48</volume><fpage>612</fpage><lpage>626</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2012.08.033</pub-id><pub-id pub-id-type="pmid">23063526</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Donohoe</surname><given-names>DR</given-names></name><name><surname>Holley</surname><given-names>D</given-names></name><name><surname>Collins</surname><given-names>LB</given-names></name><name><surname>Montgomery</surname><given-names>SA</given-names></name><name><surname>Whitmore</surname><given-names>AC</given-names></name><name><surname>Hillhouse</surname><given-names>A</given-names></name><name><surname>Curry</surname><given-names>KP</given-names></name><name><surname>Renner</surname><given-names>SW</given-names></name><name><surname>Greenwalt</surname><given-names>A</given-names></name><name><surname>Ryan</surname><given-names>EP</given-names></name><name><surname>Godfrey</surname><given-names>V</given-names></name><name><surname>Heise</surname><given-names>MT</given-names></name><name><surname>Threadgill</surname><given-names>DS</given-names></name><name><surname>Han</surname><given-names>A</given-names></name><name><surname>Swenberg</surname><given-names>JA</given-names></name><name><surname>Threadgill</surname><given-names>DW</given-names></name><name><surname>Bultman</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>A gnotobiotic mouse model demonstrates that dietary fiber protects against colorectal tumorigenesis in a microbiota- and butyrate-dependent manner</article-title><source>Cancer Discovery</source><volume>4</volume><fpage>1387</fpage><lpage>1397</lpage><pub-id pub-id-type="doi">10.1158/2159-8290.CD-14-0501</pub-id><pub-id pub-id-type="pmid">25266735</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Krautkramer</surname><given-names>KA</given-names></name><name><surname>Feldman</surname><given-names>JL</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic Regulation of Histone Post-Translational Modifications</article-title><source>ACS Chemical Biology</source><volume>10</volume><fpage>95</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.1021/cb500846u</pub-id><pub-id pub-id-type="pmid">25562692</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujino</surname><given-names>T</given-names></name><name><surname>Kondo</surname><given-names>J</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name><name><surname>Morikawa</surname><given-names>K</given-names></name><name><surname>Yamamoto</surname><given-names>TT</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Acetyl-CoA synthetase 2, a mitochondrial matrix enzyme involved in the oxidation of acetate</article-title><source>The Journal of Biological Chemistry</source><volume>276</volume><fpage>11420</fpage><lpage>11426</lpage><pub-id pub-id-type="doi">10.1074/jbc.M008782200</pub-id><pub-id pub-id-type="pmid">11150295</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Yin</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Ward</surname><given-names>RE</given-names></name><name><surname>Martin</surname><given-names>RJ</given-names></name><name><surname>Lefevre</surname><given-names>M</given-names></name><name><surname>Cefalu</surname><given-names>WT</given-names></name><name><surname>Ye</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Butyrate Improves Insulin Sensitivity and Increases Energy Expenditure in Mice</article-title><source>Diabetes</source><volume>58</volume><fpage>1509</fpage><lpage>1517</lpage><pub-id pub-id-type="doi">10.2337/db08-1637</pub-id><pub-id pub-id-type="pmid">19366864</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Lin</surname><given-names>SH</given-names></name><name><surname>Ren</surname><given-names>F</given-names></name><name><surname>Li</surname><given-names>JT</given-names></name><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Yao</surname><given-names>CB</given-names></name><name><surname>Yang</surname><given-names>HB</given-names></name><name><surname>Jiang</surname><given-names>SX</given-names></name><name><surname>Yan</surname><given-names>GQ</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Cai</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>W</given-names></name><name><surname>Yang</surname><given-names>PY</given-names></name><name><surname>Lei</surname><given-names>QY</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Acetate functions as an epigenetic metabolite to promote lipid synthesis under hypoxia</article-title><source>Nature Communications</source><volume>7</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1038/ncomms11960</pub-id><pub-id pub-id-type="pmid">27357947</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gibson</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>The intracellular target of butyrate’s actions: HDAC or HDON’T?</article-title><source>Gut</source><volume>46</volume><fpage>447</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1136/gut.46.4.447</pub-id><pub-id pub-id-type="pmid">10716666</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodman</surname><given-names>RH</given-names></name><name><surname>Smolik</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>CBP/p300 in cell growth, transformation, and development</article-title><source>Genes &amp; Development</source><volume>14</volume><fpage>1553</fpage><lpage>1577</lpage><pub-id pub-id-type="doi">10.1101/gad.14.13.1553</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goudarzi</surname><given-names>A</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Barral</surname><given-names>S</given-names></name><name><surname>Kwon</surname><given-names>OK</given-names></name><name><surname>Qi</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>Z</given-names></name><name><surname>Buchou</surname><given-names>T</given-names></name><name><surname>Vitte</surname><given-names>A-L</given-names></name><name><surname>He</surname><given-names>T</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Montellier</surname><given-names>E</given-names></name><name><surname>Gaucher</surname><given-names>J</given-names></name><name><surname>Curtet</surname><given-names>S</given-names></name><name><surname>Debernardi</surname><given-names>A</given-names></name><name><surname>Charbonnier</surname><given-names>G</given-names></name><name><surname>Puthier</surname><given-names>D</given-names></name><name><surname>Petosa</surname><given-names>C</given-names></name><name><surname>Panne</surname><given-names>D</given-names></name><name><surname>Rousseaux</surname><given-names>S</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Khochbin</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Dynamic Competing Histone H4 K5K8 Acetylation and Butyrylation Are Hallmarks of Highly Active Gene Promoters</article-title><source>Molecular Cell</source><volume>62</volume><fpage>169</fpage><lpage>180</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.03.014</pub-id><pub-id pub-id-type="pmid">27105113</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Granja</surname><given-names>AG</given-names></name><name><surname>Perkins</surname><given-names>ND</given-names></name><name><surname>Revilla</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A238L Inhibits NF-ATc2, NF-κB, and c-Jun Activation through a Novel Mechanism Involving Protein Kinase C-θ-Mediated Up-Regulation of the Amino-Terminal Transactivation Domain of p300</article-title><source>The Journal of Immunology</source><volume>180</volume><fpage>2429</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.180.4.2429</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hague</surname><given-names>A</given-names></name><name><surname>Manning</surname><given-names>AM</given-names></name><name><surname>Hanlon</surname><given-names>KA</given-names></name><name><surname>Huschtscha</surname><given-names>LI</given-names></name><name><surname>Hart</surname><given-names>D</given-names></name><name><surname>Paraskeva</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Sodium butyrate induces apoptosis in human colonic tumour cell lines in a p53-independent pathway: Implications for the possible role of dietary fibre in the prevention of large-bowel cancer</article-title><source>Ternational Journal of Cancer</source><volume>55</volume><fpage>498</fpage><lpage>505</lpage><pub-id pub-id-type="doi">10.1002/ijc.2910550329</pub-id><pub-id pub-id-type="pmid">8397167</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamer</surname><given-names>HM</given-names></name><name><surname>Jonkers</surname><given-names>D</given-names></name><name><surname>Venema</surname><given-names>K</given-names></name><name><surname>Vanhoutvin</surname><given-names>S</given-names></name><name><surname>Troost</surname><given-names>FJ</given-names></name><name><surname>Brummer</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Review article: The role of butyrate on colonic function</article-title><source>Alimentary Pharmacology &amp; Therapeutics</source><volume>27</volume><fpage>104</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2036.2007.03562.x</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>RA</given-names></name><name><surname>Kuo</surname><given-names>YM</given-names></name><name><surname>Andrews</surname><given-names>AJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Differences in Specificity and Selectivity Between CBP and p300 Acetylation of Histone H3 and H3/H4</article-title><source>Biochemistry</source><volume>52</volume><fpage>5746</fpage><lpage>5759</lpage><pub-id pub-id-type="doi">10.1021/bi400684q</pub-id><pub-id pub-id-type="pmid">23862699</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinnebusch</surname><given-names>BF</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Wu</surname><given-names>JT</given-names></name><name><surname>Archer</surname><given-names>SY</given-names></name><name><surname>Hodin</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>The Effects of Short-Chain Fatty Acids on Human Colon Cancer Cell Phenotype Are Associated with Histone Hyperacetylation</article-title><source>The Journal of Nutrition</source><volume>132</volume><fpage>1012</fpage><lpage>1017</lpage><pub-id pub-id-type="doi">10.1093/jn/132.5.1012</pub-id><pub-id pub-id-type="pmid">11983830</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>CW</given-names></name><name><surname>Shou</surname><given-names>D</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Khuc</surname><given-names>T</given-names></name><name><surname>Dai</surname><given-names>S</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name><name><surname>Klumpp-Thomas</surname><given-names>C</given-names></name><name><surname>Xia</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Identification of HDAC Inhibitors Using a Cell-Based HDAC I/II Assay</article-title><source>Journal of Biomolecular Screening</source><volume>21</volume><fpage>643</fpage><lpage>652</lpage><pub-id pub-id-type="doi">10.1177/1087057116629381</pub-id><pub-id pub-id-type="pmid">26858181</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huber</surname><given-names>K</given-names></name><name><surname>Doyon</surname><given-names>G</given-names></name><name><surname>Plaks</surname><given-names>J</given-names></name><name><surname>Fyne</surname><given-names>E</given-names></name><name><surname>Mellors</surname><given-names>JW</given-names></name><name><surname>Sluis-Cremer</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Inhibitors of histone deacetylases: Correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells</article-title><source>The Journal of Biological Chemistry</source><volume>286</volume><fpage>22211</fpage><lpage>22218</lpage><pub-id pub-id-type="doi">10.1074/jbc.M110.180224</pub-id><pub-id pub-id-type="pmid">21531716</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>D</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name><name><surname>Kimura</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Regulation of Energy Homeostasis by GPR41</article-title><source>Frontiers in Endocrinology</source><volume>5</volume><elocation-id>81</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2014.00081</pub-id><pub-id pub-id-type="pmid">24904531</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jain</surname><given-names>S</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><name><surname>Mitrani</surname><given-names>LR</given-names></name><name><surname>Bishopric</surname><given-names>NH</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Auto-acetylation stabilizes p300 in cardiac myocytes during acute oxidative stress, promoting STAT3 accumulation and cell survival</article-title><source>Breast Cancer Research and Treatment</source><volume>135</volume><fpage>103</fpage><lpage>114</lpage><pub-id pub-id-type="doi">10.1007/s10549-012-2069-6</pub-id><pub-id pub-id-type="pmid">22562121</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jenkins</surname><given-names>DJ</given-names></name><name><surname>Vuksan</surname><given-names>V</given-names></name><name><surname>Kendall</surname><given-names>CW</given-names></name><name><surname>Würsch</surname><given-names>P</given-names></name><name><surname>Jeffcoat</surname><given-names>R</given-names></name><name><surname>Waring</surname><given-names>S</given-names></name><name><surname>Mehling</surname><given-names>CC</given-names></name><name><surname>Vidgen</surname><given-names>E</given-names></name><name><surname>Augustin</surname><given-names>LS</given-names></name><name><surname>Wong</surname><given-names>E</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Physiological effects of resistant starches on fecal bulk, short chain fatty acids, blood lipids and glycemic index</article-title><source>Journal of the American College of Nutrition</source><volume>17</volume><fpage>609</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1080/07315724.1998.10718810</pub-id><pub-id pub-id-type="pmid">9853541</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaczmarska</surname><given-names>Z</given-names></name><name><surname>Ortega</surname><given-names>E</given-names></name><name><surname>Goudarzi</surname><given-names>A</given-names></name><name><surname>Huang</surname><given-names>H</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><name><surname>Márquez</surname><given-names>JA</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Khochbin</surname><given-names>S</given-names></name><name><surname>Panne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Structure of p300 in complex with acyl-CoA variants</article-title><source>Nature Chemical Biology</source><volume>13</volume><fpage>21</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1038/nchembio.2217</pub-id><pub-id pub-id-type="pmid">27820805</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karanam</surname><given-names>B</given-names></name><name><surname>Jiang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Kelleher</surname><given-names>NL</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Kinetic and Mass Spectrometric Analysis of p300 Histone Acetyltransferase Domain Autoacetylation</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>40292</fpage><lpage>40301</lpage><pub-id pub-id-type="doi">10.1074/jbc.M608813200</pub-id><pub-id pub-id-type="pmid">17065153</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karch</surname><given-names>KR</given-names></name><name><surname>Denizio</surname><given-names>JE</given-names></name><name><surname>Black</surname><given-names>BE</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Identification and interrogation of combinatorial histone modifications</article-title><source>Frontiers in Genetics</source><volume>4</volume><elocation-id>264</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2013.00264</pub-id><pub-id pub-id-type="pmid">24391660</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kebede</surname><given-names>AF</given-names></name><name><surname>Nieborak</surname><given-names>A</given-names></name><name><surname>Shahidian</surname><given-names>LZ</given-names></name><name><surname>Le Gras</surname><given-names>S</given-names></name><name><surname>Richter</surname><given-names>F</given-names></name><name><surname>Gómez</surname><given-names>DA</given-names></name><name><surname>Baltissen</surname><given-names>MP</given-names></name><name><surname>Meszaros</surname><given-names>G</given-names></name><name><surname>Magliarelli</surname><given-names>HDF</given-names></name><name><surname>Taudt</surname><given-names>A</given-names></name><name><surname>Margueron</surname><given-names>R</given-names></name><name><surname>Colomé-Tatché</surname><given-names>M</given-names></name><name><surname>Ricci</surname><given-names>R</given-names></name><name><surname>Daujat</surname><given-names>S</given-names></name><name><surname>Vermeulen</surname><given-names>M</given-names></name><name><surname>Mittler</surname><given-names>G</given-names></name><name><surname>Schneider</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Histone propionylation is a mark of active chromatin</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>24</volume><fpage>1048</fpage><lpage>1056</lpage><pub-id pub-id-type="doi">10.1038/nsmb.3490</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kelly</surname><given-names>RDW</given-names></name><name><surname>Chandru</surname><given-names>A</given-names></name><name><surname>Watson</surname><given-names>PJ</given-names></name><name><surname>Song</surname><given-names>Y</given-names></name><name><surname>Blades</surname><given-names>M</given-names></name><name><surname>Robertson</surname><given-names>NS</given-names></name><name><surname>Jamieson</surname><given-names>AG</given-names></name><name><surname>Schwabe</surname><given-names>JWR</given-names></name><name><surname>Cowley</surname><given-names>SM</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Histone deacetylase (HDAC) 1 and 2 complexes regulate both histone acetylation and crotonylation in vivo</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>14690</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-32927-9</pub-id><pub-id pub-id-type="pmid">30279482</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kespohl</surname><given-names>M</given-names></name><name><surname>Vachharajani</surname><given-names>N</given-names></name><name><surname>Luu</surname><given-names>M</given-names></name><name><surname>Harb</surname><given-names>H</given-names></name><name><surname>Pautz</surname><given-names>S</given-names></name><name><surname>Wolff</surname><given-names>S</given-names></name><name><surname>Sillner</surname><given-names>N</given-names></name><name><surname>Walker</surname><given-names>A</given-names></name><name><surname>Schmitt-Kopplin</surname><given-names>P</given-names></name><name><surname>Boettger</surname><given-names>T</given-names></name><name><surname>Renz</surname><given-names>H</given-names></name><name><surname>Offermanns</surname><given-names>S</given-names></name><name><surname>Steinhoff</surname><given-names>U</given-names></name><name><surname>Visekruna</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Microbial Metabolite Butyrate Induces Expression of Th1-Associated Factors in CD4+ T Cells</article-title><source>Frontiers in Immunology</source><volume>8</volume><elocation-id>1036</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2017.01036</pub-id><pub-id pub-id-type="pmid">28894447</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kiefer</surname><given-names>J</given-names></name><name><surname>Beyer-Sehlmeyer</surname><given-names>G</given-names></name><name><surname>Pool-Zobel</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Mixtures of SCFA, composed according to physiologically available concentrations in the gut lumen, modulate histone acetylation in human HT29 colon cancer cells</article-title><source>The British Journal of Nutrition</source><volume>96</volume><fpage>803</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1017/BJN20061948</pub-id><pub-id pub-id-type="pmid">17092367</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koh</surname><given-names>A</given-names></name><name><surname>De Vadder</surname><given-names>F</given-names></name><name><surname>Kovatcheva-Datchary</surname><given-names>P</given-names></name><name><surname>Bäckhed</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>From Dietary Fiber to Host Physiology: Short-Chain Fatty Acids as Key Bacterial Metabolites</article-title><source>Cell</source><volume>165</volume><fpage>1332</fpage><lpage>1345</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2016.05.041</pub-id><pub-id pub-id-type="pmid">27259147</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouzarides</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Chromatin Modifications and Their Function</article-title><source>Cell</source><volume>128</volume><fpage>693</fpage><lpage>705</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2007.02.005</pub-id><pub-id pub-id-type="pmid">17320507</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krautkramer</surname><given-names>K. A</given-names></name><name><surname>Reiter</surname><given-names>L</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name><name><surname>Dowell</surname><given-names>JA</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Quantification of SAHA-Dependent Changes in Histone Modifications Using Data-Independent Acquisition Mass Spectrometry</article-title><source>Journal of Proteome Research</source><volume>14</volume><fpage>3252</fpage><lpage>3262</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.5b00245</pub-id><pub-id pub-id-type="pmid">26120868</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krautkramer</surname><given-names>KA</given-names></name><name><surname>Kreznar</surname><given-names>JH</given-names></name><name><surname>Romano</surname><given-names>KA</given-names></name><name><surname>Vivas</surname><given-names>EI</given-names></name><name><surname>Barrett-Wilt</surname><given-names>GA</given-names></name><name><surname>Rabaglia</surname><given-names>ME</given-names></name><name><surname>Keller</surname><given-names>MP</given-names></name><name><surname>Attie</surname><given-names>AD</given-names></name><name><surname>Rey</surname><given-names>FE</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Diet-Microbiota Interactions Mediate Global Epigenetic Programming in Multiple Host Tissues</article-title><source>Molecular Cell</source><volume>64</volume><fpage>982</fpage><lpage>992</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2016.10.025</pub-id><pub-id pub-id-type="pmid">27889451</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>H</given-names></name><name><surname>Lund</surname><given-names>R</given-names></name><name><surname>Laiho</surname><given-names>A</given-names></name><name><surname>Lundelin</surname><given-names>K</given-names></name><name><surname>Ley</surname><given-names>RE</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Gut microbiota as an epigenetic regulator: Pilot study based on whole-genome methylation analysis</article-title><source>MBio</source><volume>5</volume><elocation-id>e02113</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.02113-14</pub-id><pub-id pub-id-type="pmid">25516615</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lasko</surname><given-names>LM</given-names></name><name><surname>Jakob</surname><given-names>CG</given-names></name><name><surname>Edalji</surname><given-names>RP</given-names></name><name><surname>Qiu</surname><given-names>W</given-names></name><name><surname>Montgomery</surname><given-names>D</given-names></name><name><surname>Digiammarino</surname><given-names>EL</given-names></name><name><surname>Hansen</surname><given-names>TM</given-names></name><name><surname>Risi</surname><given-names>RM</given-names></name><name><surname>Frey</surname><given-names>R</given-names></name><name><surname>Manaves</surname><given-names>V</given-names></name><name><surname>Shaw</surname><given-names>B</given-names></name><name><surname>Algire</surname><given-names>M</given-names></name><name><surname>Hessler</surname><given-names>P</given-names></name><name><surname>Lam</surname><given-names>LT</given-names></name><name><surname>Uziel</surname><given-names>T</given-names></name><name><surname>Faivre</surname><given-names>E</given-names></name><name><surname>Ferguson</surname><given-names>D</given-names></name><name><surname>Buchanan</surname><given-names>FG</given-names></name><name><surname>Martin</surname><given-names>RL</given-names></name><name><surname>Torrent</surname><given-names>M</given-names></name><name><surname>Chiang</surname><given-names>GG</given-names></name><name><surname>Karukurichi</surname><given-names>K</given-names></name><name><surname>Langston</surname><given-names>JW</given-names></name><name><surname>Weinert</surname><given-names>BT</given-names></name><name><surname>Choudhary</surname><given-names>C</given-names></name><name><surname>de Vries</surname><given-names>P</given-names></name><name><surname>Van Drie</surname><given-names>JH</given-names></name><name><surname>McElligott</surname><given-names>D</given-names></name><name><surname>Kesicki</surname><given-names>E</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name><name><surname>Rosenberg</surname><given-names>SH</given-names></name><name><surname>Michaelides</surname><given-names>MR</given-names></name><name><surname>Lai</surname><given-names>A</given-names></name><name><surname>Bromberg</surname><given-names>KD</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours</article-title><source>Nature</source><volume>550</volume><fpage>128</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1038/nature24028</pub-id><pub-id pub-id-type="pmid">28953875</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leemhuis</surname><given-names>H</given-names></name><name><surname>Packman</surname><given-names>LC</given-names></name><name><surname>Nightingale</surname><given-names>KP</given-names></name><name><surname>Hollfelder</surname><given-names>F</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The Human Histone Acetyltransferase P/CAF is a Promiscuous Histone Propionyltransferase</article-title><source>Chembiochem</source><volume>9</volume><fpage>499</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1002/cbic.200700556</pub-id><pub-id pub-id-type="pmid">18247445</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levrat</surname><given-names>MA</given-names></name><name><surname>Rémésy</surname><given-names>C</given-names></name><name><surname>Demigné</surname><given-names>C</given-names></name></person-group><year iso-8601-date="1991">1991</year><article-title>High propionic acid fermentations and mineral accumulation in the cecum of rats adapted to different levels of inulin</article-title><source>The Journal of Nutrition</source><volume>121</volume><fpage>1730</fpage><lpage>1737</lpage><pub-id pub-id-type="doi">10.1093/jn/121.11.1730</pub-id><pub-id pub-id-type="pmid">1941180</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>Y</given-names></name><name><surname>Dy</surname><given-names>ABC</given-names></name><name><surname>Hagerman</surname><given-names>RJ</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The Gut Microbiota and Autism Spectrum Disorders</article-title><source>Frontiers in Cellular Neuroscience</source><volume>11</volume><elocation-id>120</elocation-id><pub-id pub-id-type="doi">10.3389/fncel.2017.00120</pub-id><pub-id pub-id-type="pmid">28503135</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HV</given-names></name><name><surname>Frassetto</surname><given-names>A</given-names></name><name><surname>Kowalik</surname><given-names>EJ</given-names></name><name><surname>Nawrocki</surname><given-names>AR</given-names></name><name><surname>Lu</surname><given-names>MM</given-names></name><name><surname>Kosinski</surname><given-names>JR</given-names></name><name><surname>Hubert</surname><given-names>JA</given-names></name><name><surname>Szeto</surname><given-names>D</given-names></name><name><surname>Yao</surname><given-names>X</given-names></name><name><surname>Forrest</surname><given-names>G</given-names></name><name><surname>Marsh</surname><given-names>DJ</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e35240</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0035240</pub-id><pub-id pub-id-type="pmid">22506074</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>K</given-names></name><name><surname>Thompson</surname><given-names>PR</given-names></name><name><surname>Hwang</surname><given-names>Y</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>The structural basis of protein acetylation by the p300/CBP transcriptional coactivator</article-title><source>Nature</source><volume>451</volume><fpage>846</fpage><lpage>850</lpage><pub-id pub-id-type="doi">10.1038/nature06546</pub-id><pub-id pub-id-type="pmid">18273021</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>YN</given-names></name><name><surname>Liu</surname><given-names>TT</given-names></name><name><surname>Fan</surname><given-names>YL</given-names></name><name><surname>Niu</surname><given-names>DM</given-names></name><name><surname>Chien</surname><given-names>YH</given-names></name><name><surname>Chou</surname><given-names>YY</given-names></name><name><surname>Lee</surname><given-names>NC</given-names></name><name><surname>Hsiao</surname><given-names>KJ</given-names></name><name><surname>Chiu</surname><given-names>YH</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Measuring propionyl-CoA carboxylase activity in phytohemagglutinin stimulated lymphocytes using high performance liquid chromatography</article-title><source>Clinica Chimica Acta; International Journal of Clinical Chemistry</source><volume>453</volume><fpage>13</fpage><lpage>20</lpage><pub-id pub-id-type="doi">10.1016/j.cca.2015.11.023</pub-id><pub-id pub-id-type="pmid">26620954</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Cooper</surname><given-names>DE</given-names></name><name><surname>Cluntun</surname><given-names>AA</given-names></name><name><surname>Warmoes</surname><given-names>MO</given-names></name><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Reid</surname><given-names>MA</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lund</surname><given-names>PJ</given-names></name><name><surname>Lopes</surname><given-names>M</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>Kirsch</surname><given-names>DG</given-names></name><name><surname>Locasale</surname><given-names>JW</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Acetate Production from Glucose and Coupling to Mitochondrial Metabolism in Mammals</article-title><source>Cell</source><volume>175</volume><fpage>502</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.08.040</pub-id><pub-id pub-id-type="pmid">30245009</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>2-Hydrazinoquinoline as a Derivatization Agent for LC-MS-Based Metabolomic Investigation of Diabetic Ketoacidosis</article-title><source>Metabolites</source><volume>3</volume><fpage>993</fpage><lpage>1010</lpage><pub-id pub-id-type="doi">10.3390/metabo3040993</pub-id><pub-id pub-id-type="pmid">24958262</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luong</surname><given-names>A</given-names></name><name><surname>Hannah</surname><given-names>VC</given-names></name><name><surname>Brown</surname><given-names>MS</given-names></name><name><surname>Goldstein</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Molecular characterization of human acetyl-CoA synthetase, an enzyme regulated by sterol regulatory element-binding proteins</article-title><source>The Journal of Biological Chemistry</source><volume>275</volume><fpage>26458</fpage><lpage>26466</lpage><pub-id pub-id-type="doi">10.1074/jbc.M004160200</pub-id><pub-id pub-id-type="pmid">10843999</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>PA</given-names></name><name><surname>Breslow</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug</article-title><source>Nature Biotechnology</source><volume>25</volume><fpage>84</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.1038/nbt1272</pub-id><pub-id pub-id-type="pmid">17211407</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsono</surname><given-names>Y</given-names></name><name><surname>Illman</surname><given-names>RJ</given-names></name><name><surname>Clarke</surname><given-names>JM</given-names></name><name><surname>Trimble</surname><given-names>RP</given-names></name><name><surname>Topping</surname><given-names>DL</given-names></name></person-group><year iso-8601-date="1993">1993</year><article-title>Plasma lipids and large bowel volatile fatty acids in pigs fed on white rice, brown rice and rice bran</article-title><source>The British Journal of Nutrition</source><volume>70</volume><fpage>503</fpage><lpage>513</lpage><pub-id pub-id-type="doi">10.1079/bjn19930144</pub-id><pub-id pub-id-type="pmid">8260477</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milton</surname><given-names>SG</given-names></name><name><surname>Mathew</surname><given-names>OP</given-names></name><name><surname>Yatsu</surname><given-names>FM</given-names></name><name><surname>Ranganna</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Differential Cellular and Molecular Effects of Butyrate and Trichostatin A on Vascular Smooth Muscle Cells</article-title><source>Pharmaceuticals</source><volume>5</volume><fpage>925</fpage><lpage>943</lpage><pub-id pub-id-type="doi">10.3390/ph5090925</pub-id><pub-id pub-id-type="pmid">24280698</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Montgomery</surname><given-names>DC</given-names></name><name><surname>Sorum</surname><given-names>AW</given-names></name><name><surname>Guasch</surname><given-names>L</given-names></name><name><surname>Nicklaus</surname><given-names>MC</given-names></name><name><surname>Meier</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Metabolic Regulation of Histone Acetyltransferases by Endogenous Acyl-CoA Cofactors</article-title><source>Chemistry &amp; Biology</source><volume>22</volume><fpage>1030</fpage><lpage>1039</lpage><pub-id pub-id-type="doi">10.1016/j.chembiol.2015.06.015</pub-id><pub-id pub-id-type="pmid">26190825</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Müller</surname><given-names>M</given-names></name><name><surname>Hernández</surname><given-names>MAG</given-names></name><name><surname>Goossens</surname><given-names>GH</given-names></name><name><surname>Reijnders</surname><given-names>D</given-names></name><name><surname>Holst</surname><given-names>JJ</given-names></name><name><surname>Jocken</surname><given-names>JWE</given-names></name><name><surname>van Eijk</surname><given-names>H</given-names></name><name><surname>Canfora</surname><given-names>EE</given-names></name><name><surname>Blaak</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Circulating but not faecal short-chain fatty acids are related to insulin sensitivity, lipolysis and GLP-1 concentrations in humans</article-title><source>Scientific Reports</source><volume>9</volume><fpage>1</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1038/s41598-019-48775-0</pub-id><pub-id pub-id-type="pmid">31467327</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muschet</surname><given-names>C</given-names></name><name><surname>Möller</surname><given-names>G</given-names></name><name><surname>Prehn</surname><given-names>C</given-names></name><name><surname>de Angelis</surname><given-names>MH</given-names></name><name><surname>Adamski</surname><given-names>J</given-names></name><name><surname>Tokarz</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Removing the bottlenecks of cell culture metabolomics: Fast normalization procedure, correlation of metabolites to cell number, and impact of the cell harvesting method</article-title><source>Metabolomics</source><volume>12</volume><elocation-id>151</elocation-id><pub-id pub-id-type="doi">10.1007/s11306-016-1104-8</pub-id><pub-id pub-id-type="pmid">27729828</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ortega</surname><given-names>E</given-names></name><name><surname>Rengachari</surname><given-names>S</given-names></name><name><surname>Ibrahim</surname><given-names>Z</given-names></name><name><surname>Hoghoughi</surname><given-names>N</given-names></name><name><surname>Gaucher</surname><given-names>J</given-names></name><name><surname>Holehouse</surname><given-names>AS</given-names></name><name><surname>Khochbin</surname><given-names>S</given-names></name><name><surname>Panne</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Transcription factor dimerization activates the p300 acetyltransferase</article-title><source>Nature</source><volume>562</volume><fpage>538</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0621-1</pub-id><pub-id pub-id-type="pmid">30323286</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parada Venegas</surname><given-names>D</given-names></name><name><surname>De la Fuente</surname><given-names>MK</given-names></name><name><surname>Landskron</surname><given-names>G</given-names></name><name><surname>González</surname><given-names>MJ</given-names></name><name><surname>Quera</surname><given-names>R</given-names></name><name><surname>Dijkstra</surname><given-names>G</given-names></name><name><surname>Harmsen</surname><given-names>HJM</given-names></name><name><surname>Faber</surname><given-names>KN</given-names></name><name><surname>Hermoso</surname><given-names>MA</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Short Chain Fatty Acids (SCFAs)-Mediated Gut Epithelial and Immune Regulation and Its Relevance for Inflammatory Bowel Diseases</article-title><source>Frontiers in Immunology</source><volume>10</volume><elocation-id>277</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00277</pub-id><pub-id pub-id-type="pmid">30915065</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peng</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>ZR</given-names></name><name><surname>Green</surname><given-names>RS</given-names></name><name><surname>Holzman</surname><given-names>IR</given-names></name><name><surname>Lin</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Butyrate enhances the intestinal barrier by facilitating tight junction assembly via activation of AMP-activated protein kinase in Caco-2 cell monolayers</article-title><source>The Journal of Nutrition</source><volume>139</volume><fpage>1619</fpage><lpage>1625</lpage><pub-id pub-id-type="doi">10.3945/jn.109.104638</pub-id><pub-id pub-id-type="pmid">19625695</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prasad</surname><given-names>KN</given-names></name><name><surname>Sinha</surname><given-names>PK</given-names></name></person-group><year iso-8601-date="1976">1976</year><article-title>Effect of sodium butyrate on mammalian cells in culture: A review</article-title><source>Vitro</source><volume>12</volume><fpage>125</fpage><lpage>132</lpage><pub-id pub-id-type="doi">10.1007/bf02796360</pub-id><pub-id pub-id-type="pmid">2548</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Priyadarshini</surname><given-names>M</given-names></name><name><surname>Kotlo</surname><given-names>KU</given-names></name><name><surname>Dudeja</surname><given-names>PK</given-names></name><name><surname>Layden</surname><given-names>BT</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of Short Chain Fatty Acid Receptors in Intestinal Physiology and Pathophysiology</article-title><source>Comprehensive Physiology</source><volume>8</volume><fpage>1091</fpage><lpage>1115</lpage><pub-id pub-id-type="doi">10.1002/cphy.c170050</pub-id><pub-id pub-id-type="pmid">29978895</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahman</surname><given-names>MdM</given-names></name><name><surname>Kukita</surname><given-names>A</given-names></name><name><surname>Kukita</surname><given-names>T</given-names></name><name><surname>Shobuike</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Kohashi</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Two histone deacetylase inhibitors, trichostatin A and sodium butyrate, suppress differentiation into osteoclasts but not into macrophages</article-title><source>Blood</source><volume>101</volume><fpage>3451</fpage><lpage>3459</lpage><pub-id pub-id-type="doi">10.1182/blood-2002-08-2622</pub-id><pub-id pub-id-type="pmid">12511413</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rajan</surname><given-names>A</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Xue</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Class I and II Histone Deacetylase Inhibitors Differentially Regulate Thermogenic Gene Expression in Brown Adipocytes</article-title><source>Scientific Reports</source><volume>8</volume><elocation-id>13072</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-018-31560-w</pub-id><pub-id pub-id-type="pmid">30166563</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rickard</surname><given-names>KL</given-names></name><name><surname>Gibson</surname><given-names>PR</given-names></name><name><surname>Young</surname><given-names>GP</given-names></name><name><surname>Phillips</surname><given-names>WA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Activation of protein kinase C augments butyrate-induced differentiation and turnover in human colonic epithelial cells in vitro</article-title><source>Carcinogenesis</source><volume>20</volume><fpage>977</fpage><lpage>984</lpage><pub-id pub-id-type="doi">10.1093/carcin/20.6.977</pub-id><pub-id pub-id-type="pmid">10357776</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ringel</surname><given-names>AE</given-names></name><name><surname>Wolberger</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Structural basis for acyl-group discrimination by human Gcn5L2</article-title><source>Acta Crystallographica. Section D, Structural Biology</source><volume>72</volume><fpage>841</fpage><lpage>848</lpage><pub-id pub-id-type="doi">10.1107/S2059798316007907</pub-id><pub-id pub-id-type="pmid">27377381</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ríos-Covián</surname><given-names>D</given-names></name><name><surname>Ruas-Madiedo</surname><given-names>P</given-names></name><name><surname>Margolles</surname><given-names>A</given-names></name><name><surname>Gueimonde</surname><given-names>M</given-names></name><name><surname>de Los Reyes-Gavilán</surname><given-names>CG</given-names></name><name><surname>Salazar</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Intestinal Short Chain Fatty Acids and their Link with Diet and Human Health</article-title><source>Frontiers in Microbiology</source><volume>7</volume><elocation-id>185</elocation-id><pub-id pub-id-type="doi">10.3389/fmicb.2016.00185</pub-id><pub-id pub-id-type="pmid">26925050</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roediger</surname><given-names>WE</given-names></name></person-group><year iso-8601-date="1982">1982</year><article-title>Utilization of nutrients by isolated epithelial cells of the rat colon</article-title><source>Gastroenterology</source><volume>83</volume><fpage>424</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/S0016-5085(82)80339-9</pub-id><pub-id pub-id-type="pmid">7084619</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Romano</surname><given-names>KA</given-names></name><name><surname>Martinez-Del Campo</surname><given-names>A</given-names></name><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Chittim</surname><given-names>CL</given-names></name><name><surname>Vivas</surname><given-names>EI</given-names></name><name><surname>Amador-Noguez</surname><given-names>D</given-names></name><name><surname>Balskus</surname><given-names>EP</given-names></name><name><surname>Rey</surname><given-names>FE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Metabolic, Epigenetic, and Transgenerational Effects of Gut Bacterial Choline Consumption</article-title><source>Cell Host &amp; Microbe</source><volume>22</volume><fpage>279</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.07.021</pub-id><pub-id pub-id-type="pmid">28844887</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>SY</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name><name><surname>Allis</surname><given-names>CD</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Histone Acetyltransferases</article-title><source>Annual Review of Biochemistry</source><volume>70</volume><fpage>81</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.70.1.81</pub-id><pub-id pub-id-type="pmid">11395403</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sassone-Corsi</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Physiology: When metabolism and epigenetics converge</article-title><source>Science</source><volume>339</volume><fpage>148</fpage><lpage>150</lpage><pub-id pub-id-type="doi">10.1126/science.1233423</pub-id><pub-id pub-id-type="pmid">23307727</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sekhavat</surname><given-names>A</given-names></name><name><surname>Sun</surname><given-names>JM</given-names></name><name><surname>Davie</surname><given-names>JR</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Competitive inhibition of histone deacetylase activity by trichostatin A and butyrate</article-title><source>Biochemistry and Cell Biology = Biochimie et Biologie Cellulaire</source><volume>85</volume><fpage>751</fpage><lpage>758</lpage><pub-id pub-id-type="doi">10.1139/o07-145</pub-id><pub-id pub-id-type="pmid">18059533</pub-id></element-citation></ref><ref id="bib97"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sengupta</surname><given-names>S</given-names></name><name><surname>Muir</surname><given-names>JG</given-names></name><name><surname>Gibson</surname><given-names>PR</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Does butyrate protect from colorectal cancer?</article-title><source>Journal of Gastroenterology and Hepatology</source><volume>21</volume><fpage>209</fpage><lpage>218</lpage><pub-id pub-id-type="doi">10.1111/j.1440-1746.2006.04213.x</pub-id><pub-id pub-id-type="pmid">16460475</pub-id></element-citation></ref><ref id="bib98"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siavoshian</surname><given-names>S</given-names></name><name><surname>Segain</surname><given-names>JP</given-names></name><name><surname>Kornprobst</surname><given-names>M</given-names></name><name><surname>Bonnet</surname><given-names>C</given-names></name><name><surname>Cherbut</surname><given-names>C</given-names></name><name><surname>Galmiche</surname><given-names>JP</given-names></name><name><surname>Blottière</surname><given-names>HM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Butyrate and trichostatin A effects on the proliferation/differentiation of human intestinal epithelial cells: Induction of cyclin D3 and p21 expression</article-title><source>Gut</source><volume>46</volume><fpage>507</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1136/gut.46.4.507</pub-id><pub-id pub-id-type="pmid">10716680</pub-id></element-citation></ref><ref id="bib99"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sidoli</surname><given-names>S</given-names></name><name><surname>Bhanu</surname><given-names>NV</given-names></name><name><surname>Karch</surname><given-names>KR</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Complete Workflow for Analysis of Histone Post-translational Modifications Using Bottom-up Mass Spectrometry: From Histone Extraction to Data Analysis</article-title><source>Journal of Visualized Experiments</source><volume>111</volume><elocation-id>e54112</elocation-id><pub-id pub-id-type="doi">10.3791/54112</pub-id><pub-id pub-id-type="pmid">27286567</pub-id></element-citation></ref><ref id="bib100"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silva</surname><given-names>LG</given-names></name><name><surname>Ferguson</surname><given-names>BS</given-names></name><name><surname>Avila</surname><given-names>AS</given-names></name><name><surname>Faciola</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Sodium propionate and sodium butyrate effects on histone deacetylase (HDAC) activity, histone acetylation, and inflammatory gene expression in bovine mammary epithelial cells</article-title><source>Journal of Animal Science</source><volume>96</volume><fpage>5244</fpage><lpage>5252</lpage><pub-id pub-id-type="doi">10.1093/jas/sky373</pub-id><pub-id pub-id-type="pmid">30252114</pub-id></element-citation></ref><ref id="bib101"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simithy</surname><given-names>J</given-names></name><name><surname>Sidoli</surname><given-names>S</given-names></name><name><surname>Yuan</surname><given-names>Z-F</given-names></name><name><surname>Coradin</surname><given-names>M</given-names></name><name><surname>Bhanu</surname><given-names>NV</given-names></name><name><surname>Marchione</surname><given-names>DM</given-names></name><name><surname>Klein</surname><given-names>BJ</given-names></name><name><surname>Bazilevsky</surname><given-names>GA</given-names></name><name><surname>McCullough</surname><given-names>CE</given-names></name><name><surname>Magin</surname><given-names>RS</given-names></name><name><surname>Kutateladze</surname><given-names>TG</given-names></name><name><surname>Snyder</surname><given-names>NW</given-names></name><name><surname>Marmorstein</surname><given-names>R</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Characterization of histone acylations links chromatin modifications with metabolism</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>1141</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01384-9</pub-id><pub-id pub-id-type="pmid">29070843</pub-id></element-citation></ref><ref id="bib102"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Gurav</surname><given-names>A</given-names></name><name><surname>Sivaprakasam</surname><given-names>S</given-names></name><name><surname>Brady</surname><given-names>E</given-names></name><name><surname>Padia</surname><given-names>R</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Thangaraju</surname><given-names>M</given-names></name><name><surname>Prasad</surname><given-names>PD</given-names></name><name><surname>Manicassamy</surname><given-names>S</given-names></name><name><surname>Munn</surname><given-names>DH</given-names></name><name><surname>Lee</surname><given-names>JR</given-names></name><name><surname>Offermanns</surname><given-names>S</given-names></name><name><surname>Ganapathy</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Activation of Gpr109a, receptor for niacin and the commensal metabolite butyrate, suppresses colonic inflammation and carcinogenesis</article-title><source>Immunity</source><volume>40</volume><fpage>128</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2013.12.007</pub-id><pub-id pub-id-type="pmid">24412617</pub-id></element-citation></ref><ref id="bib103"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>H</given-names></name><name><surname>McCaffery</surname><given-names>JM</given-names></name><name><surname>Irizarry</surname><given-names>RA</given-names></name><name><surname>Boeke</surname><given-names>JD</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Nucleocytosolic Acetyl-Coenzyme A Synthetase Is Required for Histone Acetylation and Global Transcription</article-title><source>Molecular Cell</source><volume>23</volume><fpage>207</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2006.05.040</pub-id><pub-id pub-id-type="pmid">16857587</pub-id></element-citation></ref><ref id="bib104"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>J</given-names></name><name><surname>McKenzie</surname><given-names>C</given-names></name><name><surname>Potamitis</surname><given-names>M</given-names></name><name><surname>Thorburn</surname><given-names>AN</given-names></name><name><surname>Mackay</surname><given-names>CR</given-names></name><name><surname>Macia</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2014">2014</year><chapter-title>Chapter Three—The Role of Short-Chain Fatty Acids in Health and Disease</chapter-title><person-group person-group-type="editor"><name><surname>Alt</surname><given-names>FW</given-names></name></person-group><source>Advances in Immunology</source><publisher-name>Academic Press</publisher-name><fpage>91</fpage><lpage>119</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-800100-4.00003-9</pub-id></element-citation></ref><ref id="bib105"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thangaraju</surname><given-names>M</given-names></name><name><surname>Cresci</surname><given-names>GA</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Ananth</surname><given-names>S</given-names></name><name><surname>Gnanaprakasam</surname><given-names>JP</given-names></name><name><surname>Browning</surname><given-names>DD</given-names></name><name><surname>Mellinger</surname><given-names>JD</given-names></name><name><surname>Smith</surname><given-names>SB</given-names></name><name><surname>Digby</surname><given-names>GJ</given-names></name><name><surname>Lambert</surname><given-names>NA</given-names></name><name><surname>Prasad</surname><given-names>PD</given-names></name><name><surname>Ganapathy</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>GPR109A is a G-protein-coupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon</article-title><source>Cancer Research</source><volume>69</volume><fpage>2826</fpage><lpage>2832</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-4466</pub-id><pub-id pub-id-type="pmid">19276343</pub-id></element-citation></ref><ref id="bib106"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thomas</surname><given-names>SP</given-names></name><name><surname>Haws</surname><given-names>SA</given-names></name><name><surname>Borth</surname><given-names>LE</given-names></name><name><surname>Denu</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A practical guide for analysis of histone post-translational modifications by mass spectrometry: Best practices and pitfalls</article-title><source>Methods</source><volume>184</volume><fpage>53</fpage><lpage>60</lpage><pub-id pub-id-type="doi">10.1016/j.ymeth.2019.12.001</pub-id></element-citation></ref><ref id="bib107"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>PR</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Fulco</surname><given-names>M</given-names></name><name><surname>Pediconi</surname><given-names>N</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>An</surname><given-names>W</given-names></name><name><surname>Ge</surname><given-names>Q</given-names></name><name><surname>Roeder</surname><given-names>RG</given-names></name><name><surname>Wong</surname><given-names>J</given-names></name><name><surname>Levrero</surname><given-names>M</given-names></name><name><surname>Sartorelli</surname><given-names>V</given-names></name><name><surname>Cotter</surname><given-names>RJ</given-names></name><name><surname>Cole</surname><given-names>PA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Regulation of the p300 HAT domain via a novel activation loop</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>11</volume><fpage>308</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1038/nsmb740</pub-id></element-citation></ref><ref id="bib108"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trefely</surname><given-names>S</given-names></name><name><surname>Lovell</surname><given-names>CD</given-names></name><name><surname>Snyder</surname><given-names>NW</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Compartmentalised acyl-CoA metabolism and roles in chromatin regulation</article-title><source>Molecular Metabolism</source><volume>38</volume><elocation-id>100941</elocation-id><pub-id pub-id-type="doi">10.1016/j.molmet.2020.01.005</pub-id><pub-id pub-id-type="pmid">32199817</pub-id></element-citation></ref><ref id="bib109"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Usami</surname><given-names>M</given-names></name><name><surname>Kishimoto</surname><given-names>K</given-names></name><name><surname>Ohata</surname><given-names>A</given-names></name><name><surname>Miyoshi</surname><given-names>M</given-names></name><name><surname>Aoyama</surname><given-names>M</given-names></name><name><surname>Fueda</surname><given-names>Y</given-names></name><name><surname>Kotani</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Butyrate and trichostatin A attenuate nuclear factor kappaB activation and tumor necrosis factor alpha secretion and increase prostaglandin E2 secretion in human peripheral blood mononuclear cells</article-title><source>Nutrition Research</source><volume>28</volume><fpage>321</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/J.NUTRES.2008.02.012</pub-id><pub-id pub-id-type="pmid">19083427</pub-id></element-citation></ref><ref id="bib110"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Velázquez</surname><given-names>M</given-names></name><name><surname>Davies</surname><given-names>C</given-names></name><name><surname>Marett</surname><given-names>R</given-names></name><name><surname>Slavin</surname><given-names>JL</given-names></name><name><surname>Feirtag</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Effect of Oligosaccharides and Fibre Substitutes on Short-chain Fatty Acid Production by Human Faecal Microflora</article-title><source>Anaerobe</source><volume>6</volume><fpage>87</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1006/anae.1999.0318</pub-id></element-citation></ref><ref id="bib111"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vinolo</surname><given-names>MAR</given-names></name><name><surname>Rodrigues</surname><given-names>HG</given-names></name><name><surname>Hatanaka</surname><given-names>E</given-names></name><name><surname>Sato</surname><given-names>FT</given-names></name><name><surname>Sampaio</surname><given-names>SC</given-names></name><name><surname>Curi</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils</article-title><source>The Journal of Nutritional Biochemistry</source><volume>22</volume><fpage>849</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2010.07.009</pub-id><pub-id pub-id-type="pmid">21167700</pub-id></element-citation></ref><ref id="bib112"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogelauer</surname><given-names>M</given-names></name><name><surname>Krall</surname><given-names>AS</given-names></name><name><surname>McBrian</surname><given-names>MA</given-names></name><name><surname>Li</surname><given-names>JY</given-names></name><name><surname>Kurdistani</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Stimulation of Histone Deacetylase Activity by Metabolites of Intermediary Metabolism</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>32006</fpage><lpage>32016</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.362467</pub-id><pub-id pub-id-type="pmid">22822071</pub-id></element-citation></ref><ref id="bib113"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waldecker</surname><given-names>M</given-names></name><name><surname>Kautenburger</surname><given-names>T</given-names></name><name><surname>Daumann</surname><given-names>H</given-names></name><name><surname>Busch</surname><given-names>C</given-names></name><name><surname>Schrenk</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Inhibition of histone-deacetylase activity by short-chain fatty acids and some polyphenol metabolites formed in the colon</article-title><source>The Journal of Nutritional Biochemistry</source><volume>19</volume><fpage>587</fpage><lpage>593</lpage><pub-id pub-id-type="doi">10.1016/j.jnutbio.2007.08.002</pub-id><pub-id pub-id-type="pmid">18061431</pub-id></element-citation></ref><ref id="bib114"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Holt</surname><given-names>MV</given-names></name><name><surname>Young</surname><given-names>NL</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Early butyrate induced acetylation of histone H4 is proteoform specific and linked to methylation state</article-title><source>Epigenetics</source><volume>13</volume><fpage>519</fpage><lpage>535</lpage><pub-id pub-id-type="doi">10.1080/15592294.2018.1475979</pub-id><pub-id pub-id-type="pmid">29940793</pub-id></element-citation></ref><ref id="bib115"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wellen</surname><given-names>KE</given-names></name><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Sachdeva</surname><given-names>UM</given-names></name><name><surname>Bui</surname><given-names>TV</given-names></name><name><surname>Cross</surname><given-names>JR</given-names></name><name><surname>Thompson</surname><given-names>CB</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>ATP-Citrate Lyase Links Cellular Metabolism to Histone Acetylation</article-title><source>Science</source><volume>324</volume><fpage>1076</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1126/science.1164097</pub-id><pub-id pub-id-type="pmid">19461003</pub-id></element-citation></ref><ref id="bib116"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Miyamoto</surname><given-names>N</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Valasek</surname><given-names>MA</given-names></name><name><surname>Motoike</surname><given-names>T</given-names></name><name><surname>Kedzierski</surname><given-names>RM</given-names></name><name><surname>Yanagisawa</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41</article-title><source>PNAS</source><volume>101</volume><fpage>1045</fpage><lpage>1050</lpage><pub-id pub-id-type="doi">10.1073/pnas.2637002100</pub-id><pub-id pub-id-type="pmid">14722361</pub-id></element-citation></ref><ref id="bib117"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>YG</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Function of the Active Site Lysine Autoacetylation in Tip60 Catalysis</article-title><source>PLOS ONE</source><volume>7</volume><elocation-id>e32886</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0032886</pub-id><pub-id pub-id-type="pmid">22470428</pub-id></element-citation></ref><ref id="bib118"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yuan</surname><given-names>ZF</given-names></name><name><surname>Sidoli</surname><given-names>S</given-names></name><name><surname>Marchione</surname><given-names>DM</given-names></name><name><surname>Simithy</surname><given-names>J</given-names></name><name><surname>Janssen</surname><given-names>KA</given-names></name><name><surname>Szurgot</surname><given-names>MR</given-names></name><name><surname>Garcia</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>EpiProfile 2.0: A Computational Platform for Processing Epi-Proteomics Mass Spectrometry Data</article-title><source>Journal of Proteome Research</source><volume>17</volume><fpage>2533</fpage><lpage>2541</lpage><pub-id pub-id-type="doi">10.1021/acs.jproteome.8b00133</pub-id><pub-id pub-id-type="pmid">29790754</pub-id></element-citation></ref><ref id="bib119"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zgheib</surname><given-names>C</given-names></name><name><surname>Zouein</surname><given-names>FA</given-names></name><name><surname>Chidiac</surname><given-names>R</given-names></name><name><surname>Kurdi</surname><given-names>M</given-names></name><name><surname>Booz</surname><given-names>GW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Calyculin A Reveals Serine/Threonine Phosphatase Protein Phosphatase 1 as a Regulatory Nodal Point in Canonical Signal Transducer and Activator of Transcription 3 Signaling of Human Microvascular Endothelial Cells</article-title><source>Journal of Interferon &amp; Cytokine Research</source><volume>32</volume><fpage>87</fpage><lpage>94</lpage><pub-id pub-id-type="doi">10.1089/jir.2011.0059</pub-id><pub-id pub-id-type="pmid">22142222</pub-id></element-citation></ref><ref id="bib120"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Torres</surname><given-names>A</given-names></name><name><surname>Henry</surname><given-names>RA</given-names></name><name><surname>Trefely</surname><given-names>S</given-names></name><name><surname>Wallace</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>JV</given-names></name><name><surname>Carrer</surname><given-names>A</given-names></name><name><surname>Sengupta</surname><given-names>A</given-names></name><name><surname>Campbell</surname><given-names>SL</given-names></name><name><surname>Kuo</surname><given-names>Y-M</given-names></name><name><surname>Frey</surname><given-names>AJ</given-names></name><name><surname>Meurs</surname><given-names>N</given-names></name><name><surname>Viola</surname><given-names>JM</given-names></name><name><surname>Blair</surname><given-names>IA</given-names></name><name><surname>Weljie</surname><given-names>AM</given-names></name><name><surname>Metallo</surname><given-names>CM</given-names></name><name><surname>Snyder</surname><given-names>NW</given-names></name><name><surname>Andrews</surname><given-names>AJ</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>ATP-Citrate Lyase Controls a Glucose-to-Acetate Metabolic Switch</article-title><source>Cell Reports</source><volume>17</volume><fpage>1037</fpage><lpage>1052</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.09.069</pub-id><pub-id pub-id-type="pmid">27760311</pub-id></element-citation></ref><ref id="bib121"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>S</given-names></name><name><surname>Jang</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Uehara</surname><given-names>K</given-names></name><name><surname>Gilbert</surname><given-names>M</given-names></name><name><surname>Izzo</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Trefely</surname><given-names>S</given-names></name><name><surname>Fernandez</surname><given-names>S</given-names></name><name><surname>Carrer</surname><given-names>A</given-names></name><name><surname>Miller</surname><given-names>KD</given-names></name><name><surname>Schug</surname><given-names>ZT</given-names></name><name><surname>Snyder</surname><given-names>NW</given-names></name><name><surname>Gade</surname><given-names>TP</given-names></name><name><surname>Titchenell</surname><given-names>PM</given-names></name><name><surname>Rabinowitz</surname><given-names>JD</given-names></name><name><surname>Wellen</surname><given-names>KE</given-names></name></person-group><year iso-8601-date="2020">2020a</year><article-title>Dietary fructose feeds hepatic lipogenesis via microbiota-derived acetate</article-title><source>Nature</source><volume>579</volume><fpage>586</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-2101-7</pub-id><pub-id pub-id-type="pmid">32214246</pub-id></element-citation></ref><ref id="bib122"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Lin</surname><given-names>H</given-names></name></person-group><year iso-8601-date="2020">2020b</year><article-title>Low and high concentrations of butyrate regulate fat accumulation in chicken adipocytes via different mechanisms</article-title><source>Adipocyte</source><volume>9</volume><fpage>120</fpage><lpage>131</lpage><pub-id pub-id-type="doi">10.1080/21623945.2020.1738791</pub-id><pub-id pub-id-type="pmid">32163011</pub-id></element-citation></ref><ref id="bib123"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Q</given-names></name><name><surname>Dalgard</surname><given-names>CL</given-names></name><name><surname>Wynder</surname><given-names>C</given-names></name><name><surname>Doughty</surname><given-names>ML</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Histone deacetylase inhibitors SAHA and sodium butyrate block G1-to-S cell cycle progression in neurosphere formation by adult subventricular cells</article-title><source>BMC Neuroscience</source><volume>12</volume><elocation-id>50</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2202-12-50</pub-id><pub-id pub-id-type="pmid">21615950</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72171.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><p>This study investigates the mechanism of agents like butyrate as metabolites that affect histone acetylation. The authors make the unexpected and interesting finding that such metabolites can stimulate the activity of the acetyltransferase p300 rather than the commonly accepted concept that they block histone deacetylases. The authors show evidence that p300 stimulation involves acylation of Lys residues on its autoinhibitory loop. The authors have effectively responded to prior concerns raised by the reviewers. This study should be of broad interest to the epigenetic research community.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72171.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Shi</surname><given-names>Xiaobing</given-names></name><role>Reviewing Editor</role><aff><institution>Van Andel Institute</institution><country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Khochbin</surname><given-names>Saadi</given-names></name><role>Reviewer</role></contrib></contrib-group></front-stub><body><boxed-text id="box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>Thank you for submitting your article &quot;Short-chain fatty acids activate acetyltransferase p300&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Philip Cole as the Senior Editor. The following individual involved in review of your submission has agreed to reveal their identity: Saadi Khochbin (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are long thought to function as inhibitors of HDACs. Here, Thomas and Denu challenge this textbook dogma by providing argument that activation of CBP/p300 catalytic activity following AIL domain acylation is a major contributor to histone hyperacetylation induced by SCFAs. In this study, the authors carry out proteomic and metabolic analyses to determine changes in histone modifications and metabolites in cells treated with SFCAs. The results show that propionate and butyrate, but not acetate, induce rapid and dose-dependent increases in histone acetylation. The propionate and butyrate are rapidly metabolized into acyl-CoAs (uM or sub-uM levels) in cells, while the cellular levels of these SCFAs remain at low concentrations (tens of μm levels) that are not able to inhibit HDACs. MS of histone PTMs suggest that the majority of new acetyl groups on acetylated histones are not generated from the C13-labeled SCFAs, suggesting that a different mechanism is at play. Interestingly, HAT assays of the nuclear extracts show propionyl- and butyryl-CoA induce does-dependent increases in the HAT activity, whereas free propionate and butyrate have no effect. in vitro HAT assays using recombinant p300 HAT show that p300 utilizes butyryl-CoA and propionyl-CoA for auto acylation, and the auto-acylation activates the enzyme of p300 HAT in a similar manner to its auto-acetylation by using acetyl-CoA. Finally, they show that inhibition of p300 enzymatic activity, but not inhibition of HDACs, reverses SFCA-induced histone hyperacetylation.</p><p>This paper reports very intriguing observations and proposes a novel but surprising idea, which in our views deserve large diffusion and should fuel new thoughts and constructive debates. SCFAs, especially butyrate, have been found to have multiple beneficial health effects in the body. Likely, the finding presented in this work will elicit more attention and research in this field to further investigate polypharmacological mechanisms of SCFAs in influencing physiology and pathology.</p><p>However, the manuscript also raises a number of questions that need to be carefully addressed. Particularly, the precise mechanisms that differentiate the action of propionate and butyrate from acetate on CBP/p300 activity remain obscure and the authors could strengthen their conclusions by some additional investigations. Acetyl-CoA is a much better cofactor than butyryl-CoA and propionyl-CoA for p300. It needs to be addressed why an acetate treatment, as opposed to propionate or butyrate treatment, does not lead to increases in CBP/p300 AIL acetylation and to an activation of these HATs. Also, this paper does not have sufficient data to suggest SFCAs do not function through HDAC inhibition in cells. The very low concentrations of propionyl-CoA and butyryl-CoA present in the cell and the only modest activation on p300 activity by the AIL acylation are also of concern.</p><p>1) A major puzzle is how the three SCFAs, acetate, propionate, and butyrate affect histone acetylation differently, under the proposed mechanism of p300 activation by autoacylation. In in vitro p300 HAT assay, acetyl-CoA exhibits the same effect as propionate and butyrate (Figure 3B, C and S4C-E) and adding acetate in medium increases acetyl-CoA levels in cells (Figure 2E and S2D). However, the increased acetyl-CoA levels fail to enhance p300 autoacetylation and activation. This discrepancy is confusing and should be resolved.</p><p>2) The authors argue that intracellular concentrations of propionate and butyrate are not high enough to inhibit HDAC in cells. However, this paper does not have sufficient data to show HDAC activities are not effectively inhibited by propionate and butyrate at low concentrations (e.g. 10 nM) in cells. Importantly, intracellular distribution of propionate and butyrate is heterogeneous. Key regions inside the cell could have disproportionally high levels of propionate and butyrate to effective block HDAC activity. The authors could use target validation techniques such as cellular thermal shift assay (CETSA) to validate or invalidate if butyrate binds HDACs in cells at low concentrations (e.g., under 1 mM treatment condition).</p><p>3) Butyryl-CoA is a very poor substrate of p300 compared with acetyl-CoA and propionyl-CoA, however butyrate leads to the strongest histone hyperacetylation. In addition, in cells butyryl-CoA is at only tens of nM levels compared to sub-uM of acetyl-CoA and propionyl-CoA (Figure 3). This discrepancy needs to be resolved. Figure 3A also needs to be carefully and quantitatively re-examined to substantiate if butyryl-CoA is a better substrate than acetyl-CoA and propionyl-CoA in p300 autoacylation.</p><p>4) The mechanism underlying the conversion of propionate and butyrate into their corresponding CoA derivatives described here as a key event in activating CBP/p300 is not clear. Published data indicate that ACSS2 is able to synthesize crotonyl-CoA (PMID 25818647). It is very likely that ACSS2 can also synthesize propionyl-CoA and butyryl-CoA, and if so, its down regulation should affect p300 auto-acylation (PMID 25818647). However, here the authors show that ACSS2 knock-down has no significant effect on propionate or butyrate-induced histone acetylation. Could this be due to inefficient knock-down of ACSS2? Experimental data are needed to address this discrepancy.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.72171.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>Short-chain fatty acids (SCFAs), such as acetate, propionate, and butyrate, are long thought to function as inhibitors of HDACs. Here, Thomas and Denu challenge this textbook dogma by providing argument that activation of CBP/p300 catalytic activity following AIL domain acylation is a major contributor to histone hyperacetylation induced by SCFAs. In this study, the authors carry out proteomic and metabolic analyses to determine changes in histone modifications and metabolites in cells treated with SFCAs. The results show that propionate and butyrate, but not acetate, induce rapid and dose-dependent increases in histone acetylation. The propionate and butyrate are rapidly metabolized into acyl-CoAs (uM or sub-uM levels) in cells, while the cellular levels of these SCFAs remain at low concentrations (tens of μm levels) that are not able to inhibit HDACs. MS of histone PTMs suggest that the majority of new acetyl groups on acetylated histones are not generated from the C13-labeled SCFAs, suggesting that a different mechanism is at play. Interestingly, HAT assays of the nuclear extracts show propionyl- and butyryl-CoA induce does-dependent increases in the HAT activity, whereas free propionate and butyrate have no effect. in vitro HAT assays using recombinant p300 HAT show that p300 utilizes butyryl-CoA and propionyl-CoA for auto acylation, and the auto-acylation activates the enzyme of p300 HAT in a similar manner to its auto-acetylation by using acetyl-CoA. Finally, they show that inhibition of p300 enzymatic activity, but not inhibition of HDACs, reverses SFCA-induced histone hyperacetylation.</p><p>This paper reports very intriguing observations and proposes a novel but surprising idea, which in our views deserve large diffusion and should fuel new thoughts and constructive debates. SCFAs, especially butyrate, have been found to have multiple beneficial health effects in the body. Likely, the finding presented in this work will elicit more attention and research in this field to further investigate polypharmacological mechanisms of SCFAs in influencing physiology and pathology.</p><p>However, the manuscript also raises a number of questions that need to be carefully addressed. Particularly, the precise mechanisms that differentiate the action of propionate and butyrate from acetate on CBP/p300 activity remain obscure and the authors could strengthen their conclusions by some additional investigations. Acetyl-CoA is a much better cofactor than butyryl-CoA and propionyl-CoA for p300. It needs to be addressed why an acetate treatment, as opposed to propionate or butyrate treatment, does not lead to increases in CBP/p300 AIL acetylation and to an activation of these HATs. Also, this paper does not have sufficient data to suggest SFCAs do not function through HDAC inhibition in cells. The very low concentrations of propionyl-CoA and butyryl-CoA present in the cell and the only modest activation on p300 activity by the AIL acylation are also of concern.</p></disp-quote><p>We thank the reviewers for their insightful summary and excitement for this novel work.</p><disp-quote content-type="editor-comment"><p>1) A major puzzle is how the three SCFAs, acetate, propionate, and butyrate affect histone acetylation differently, under the proposed mechanism of p300 activation by autoacylation. In in vitro p300 HAT assay, acetyl-CoA exhibits the same effect as propionate and butyrate (Figure 3B, C and S4C-E) and adding acetate in medium increases acetyl-CoA levels in cells (Figure 2E and S2D). However, the increased acetyl-CoA levels fail to enhance p300 autoacetylation and activation. This discrepancy is confusing and should be resolved.</p></disp-quote><p>First, an important clarification: Acetate addition does not lead to substantial increases in acetyl-CoA, which is consistent with the lack of stimulated histone acetylation. Thus, we would argue that our proposed mechanism is well-aligned with the observations. As stated in lines 284-301, the central difference amongst the three SCFAs is that exogenously added acetate is not rapidly converted to acetyl-CoA. The reviewer is right to notice that total levels of acetyl-carnitine and acetyl-CoA do increase over time in Figures 2E and S2D; however, this occurs in every condition (including the untreated control), indicating that the increase in acetyl-CoA is due to factors other than exogenous addition of acetate. Instead, levels of labeled acetylCoA/carnitine in our acetate treated samples remains low, and total levels closely mirror those in untreated controls.</p><p>Importantly, these results indicate that in the cell lines we tested, the activity of ACSS2 (acetyl-CoA synthetase (nuclear-cytoplasmic)) is relatively low compared to the (unknown) synthetases that convert propionate and butyrate to their respective esterified CoA forms. This is another extremely critical point of our work and is further detailed in subsequent responses to reviewers.</p><disp-quote content-type="editor-comment"><p>2) The authors argue that intracellular concentrations of propionate and butyrate are not high enough to inhibit HDAC in cells. However, this paper does not have sufficient data to show HDAC activities are not effectively inhibited by propionate and butyrate at low concentrations (e.g. 10 nM) in cells. Importantly, intracellular distribution of propionate and butyrate is heterogeneous. Key regions inside the cell could have disproportionally high levels of propionate and butyrate to effective block HDAC activity. The authors could use target validation techniques such as cellular thermal shift assay (CETSA) to validate or invalidate if butyrate binds HDACs in cells at low concentrations (e.g., under 1 mM treatment condition).</p></disp-quote><p>We do not argue that HDAC inhibition does not occur during high physiological exposure to SCFAs, but that given the compelling data in this paper and with a more insightful review of prior studies, the contribution by HDAC inhibition could be much lower than previously thought. This case can be made best with low levels of propionate treatment, which on a molar-to-molar basis leads to similar hyperacetylation as butyrate, despite the fact that butyrate is a much better HDAC inhibitor than propionate. We fully understand that we are proposing a novel mechanism that appears to go against the prevailing theory. However, these mechanisms are not mutually exclusive. We argue that under non-supra physiological levels of SCFAs, p300/CBP HAT activation is a viable mechanism to explain histone hyperacetylation.</p><p>Regarding the possibility that different compartments of the cell might have “disproportionally high levels of propionate and butyrate to effective block HDAC activity”: this is certainly possible, but our studies are focused on nuclear and cytoplasmic events, where we have measured total SCFA levels. We are not aware of any studies that show free SCFA concentrations are different between nucleus and cytoplasm, and given that these compartments make up the majority of the cell volume, we believe our numbers are accurate reflections of SCFAs concentrations for the processes we investigated.</p><p>The reviewer suggested that we could perform “cellular thermal shift assay (CETSA) to validate or invalidate if butyrate binds HDACs in cells at low concentrations.” This is an interesting suggestion, but unfortunately interpreting such an experiment is not as straight forward as suggested. Since there is currently no consensus as to which specific HDACs are inhibited by butyrate, CETSA assays would likely prove inconclusive since thermal shifts for every HDAC would be difficult to report in a single assay. We believe our data measuring the apparent IC50 (inhibition) of SCFAs in nuclear extracts provides a more direct assessment of the binding to HDACs in a relevant context. To make this point more strongly, we have included the raw data in Supplemental Figure 1E. IC50 values are reported in Table 1.</p><disp-quote content-type="editor-comment"><p>3) Butyryl-CoA is a very poor substrate of p300 compared with acetyl-CoA and propionyl-CoA, however butyrate leads to the strongest histone hyperacetylation. In addition, in cells butyryl-CoA is at only tens of nM levels compared to sub-uM of acetyl-CoA and propionyl-CoA (Figure 3). This discrepancy needs to be resolved. Figure 3A also needs to be carefully and quantitatively re-examined to substantiate if butyryl-CoA is a better substrate than acetyl-CoA and propionyl-CoA in p300 autoacylation.</p></disp-quote><p>Because butyrate is the best HDAC inhibitor of the three, at higher levels (~1 mM) both HAT activation and HDAC inhibition could account for the more robust histone acetylation. However, at 100 µM, the hyperacetylation induced by propionate and butyrate are essentially identical (Figure 4). We have included a discussion of this point starting at line 352.</p><p>Our auto-acylation data in Figure 3B and 3C suggests that butyryl-CoA, propionyl-CoA acetyl-CoA and are equally effective substrates for autoacylation, at least under the conditions assayed. It is reported that butyrylCoA is a poor substrate for trans-butyrylation of histones (see Kaczmarska et al. and our data in Figure 1). However, our auto-acylation data suggests that the mechanisms for auto- and trans-acylation differ. A discussion of this point is included in lines 330-344. Our next major project is to perform a detailed mechanistic analysis of the acyl-specificity for auto-acylation, and to examine whether the resulting activity enzyme displays different specificities in trans-acetylation.</p><p>As to the concentration levels, the literature does suggest that acetyl-CoA is more abundant than propionyl- or butyryl-CoA under normal glucose-rich cellular conditions (see Simithy et al.). However, acetyl-CoA generation is tightly regulated with cell type and energy state, and the levels of short-chain acyl-CoAs will be dictated by the availability of extracellular SCFAs and other non-glucose metabolism, particularly amino acids and FAs. Thus, even a two-fold increase in propionyl- or butyryl-CoA could provide a new acyl-CoA pool that was previously unavailable to p300, allowing p300 to respond to specific increases in new acyl-CoA species. Another important consideration is the rate at which specific acylations are removed by deacetylases, potentially increasing the lifetime of p300 activation via certain auto-acylated forms. This will be a profoundly exciting possibility to explore.</p><disp-quote content-type="editor-comment"><p>4) The mechanism underlying the conversion of propionate and butyrate into their corresponding CoA derivatives described here as a key event in activating CBP/p300 is not clear. Published data indicate that ACSS2 is able to synthesize crotonyl-CoA (PMID 25818647). It is very likely that ACSS2 can also synthesize propionyl-CoA and butyryl-CoA, and if so, its down regulation should affect p300 auto-acylation (PMID 25818647). However, here the authors show that ACSS2 knock-down has no significant effect on propionate or butyrate-induced histone acetylation. Could this be due to inefficient knock-down of ACSS2? Experimental data are needed to address this discrepancy.</p></disp-quote><p>Although the exact mechanisms that convert propionate and butyrate to their corresponding acyl-CoAs are not yet clear (for an excellent review of current knowledge on the subject, see Trefely et al.), our data show that butyrate and propionate but not acetate are rapidly (minutes) converted to their acyl-CoAs and acyl-carnitines. While ACSS2 might appear to be a promising candidate for propionate and butyrate, our data and others suggest that ACSS2 is not likely the enzyme responsible for esterifying propionate or butyrate to CoA.</p><p>ACSS2 is highly specific for acetate. We refer this discussion to two important JBC papers, one from Brown and Goldstein (Luong et al, 2000) and the other from Fujino et al (2001). As substrates, acetate is &gt;30-fold better than propionate, and no significant activity was measured with butyrate.</p><p>Because we observe no significant increase in acetyl-CoA or hyperacetylation by acetate addition to cells, we expect that ACSS2 expression and activity is extremely low in the cell lines analyzed here. This is very common under typical cell culture growth conditions.</p><p>Thus, the knockdown of ACSS2 was predicted to exhibit little difference with acetate. Importantly, the fact that ACSS2 knockdown also had no significant effect on propionate- and butyrate-induced acyl-CoA levels or histone hyperacylation supports the restricted substrate specificity of ACSS2 (Fujino et al, and Luong et al).</p><p>We would argue that a comprehensive understanding of SCFA conversion to acylCoAs is outside the scope of this paper.</p></body></sub-article></article>